19
ORGANISATION AFRICAINE DE LA PROPRIETE INTELLECTUELLE
51 8 Inter. CI. C07D 471/04 (2018.01) 11 A61K 31/519 (2018.01)
N° 18435 A61P 29/00 (2018.01) A61P 31/12 (2018.01)
A61P 35/00 (2018.01) FASCICULE DE BREVET D'INVENTION A61P 37/00 (2018.01)
21 Numéro de dépôt : 1201700355 73 Titulaire(s): PCT/US2016/020499
GILEAD SCIENCES, INC.,
333 Lakeside Drive, 22 Date de dépôt : 02/03/2016 FOSTER CITY,
CA 94404 (US)
30 Priorité(s): Inventeur(s): 72
US n° 62/128,397 du 04/03/2015 CHIN Gregory (US) US n° 62/250,403 du 03/11/2015 METOBO Samuel E. (US) ZABLOCKI Jeff (US) MACKMAN Richard L. (US) MISH Michael R. (US) AKTOUDIANAKIS Evangelos (US) PYUN Hyung-jung (US)
24 Délivré le : 27/09/2018
74 Mandataire: GAD CONSULTANTS SCP,
B.P. 13448, YAOUNDE (CM). 45 Publié le : 15.11.2018
54 Titre: Toll like receptor modulator compounds.
57 Abrégé :
The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido [3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.
O.A.P.I. – B.P. 887, YAOUNDE (Cameroun) – Tel. (237) 222 20 57 00 – Site web: http:/www.oapi.int – Email: [email protected]
18435
TOLL LIKE RECEPTOR MODULATOR COMPOUNDS
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application Nos. 62/128397, filed March 4, 2015, and 62/250403, filed November 3, 2015, both of which are incorporated herein in their entireties for all purposes.
FIELD
100021 This application relates generally to toll like receptor modulator compounds, including diamino pyrido[3,2 D] pyrimidine compounds, and pharmaceutical compositions which, among other things, modulate toll-like receptors (e g. TLR-8), and methods of making and using them.
BACKGROUND
[0003] The toll-like receptor (TLR) family plays a fundamental role in pathogen recognition and activation of innate immunity. Toll-like receptor 8 (TLR-8) is predominantly expressed by myeloid immune cells and activation of this receptor stimulates a broad immunological response. Agonists of TLR-8 activate myeloid dendritic cells, monocytes, monocyte-derived dendridic cells and Kupffer cells leading to the production of proinflammatory cytokines and chemokines, such as interleukin-18 (IL-18), interleukin- 12 (IL-12), tumor necrosis factor-alpha (TNF-a), and interferon- gamma (IFN-y). Such agonists also promote the increased expression of co-stimulatory molecules such as CDS + cells, major histocompatibility complex molecules (MAIT, NK cells), and chemokine receptors.
[0004] Collectively, activation of these innate and adaptive immune responses induces an immune response and provides a therapeutic benefit in various conditions involving autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease (GvHD), infection, cancer, and immunodeficiency. For example, with respect to hepatitis B, activation of TLR8 on professional antigen presenting cells (pAPCs) and other intrahepatic immune cells is associated with induction of IL-12 and proinflammatory cytokines, which is expected to augment HBV-specific T cell responses, activate intrahepatic NK cells and drive reconstitution of antiviral immunity. See e.g. Wille-Reece, U. et al. JErpMed2O3, 1249-1258 (2006); Peng, G. et al.,
1 18435
Science 309, 1380-1384 (2005); Jo, J. elaL, PLoS Pathogens 10, e1004210 (2014) and Watashi, K. et al., filial Chem 288, 31715-31727(2013).
100051 Given the potential to treat a wide array of diseases, there remains a need for novel modulators of toll like receptors, for example TLR-8. Potent and selective modulators of TLR-8 that have reduced potential for off target liabilities are particularly desireable.
SUMMARY
100061 The present disclosure provides a compound of Formula (J):
R4 NH
A N NH2 R3 (0 or a pharmaceutically acceptable salt thereof, wherein: X is Nor CRI°; RI is selected from the group consisting of hydrogen, halogen, C14alkyl, CN, NRIRb —S(0)1-2R', and OR', wherein Ctalkyl is optionally substituted with 1 to 5 R2° groups; R2 is selected from the group consisting of hydrogen, halogen, C1.6alkyl, CN, — NR'Rb, —S(0)i.211' and OR', wherein Cialkyl is optionally substituted with 1 to 5 R2° groups; R3 is selected from the group consisting of hydrogen, halogen, C14alkyl, CN, — N12"Rb, —S(0)1.211', and OR', wherein CI-alkyl is optionally substituted with 1 to 5 R2° groups; R4 is C142 alkyl which is optionally substituted with 1 to 5 substituents independently selected from halogen, -OR', —NR'R b, CN, —C(0)R', — C(0)011', —C(0)NR'le, —0C(0)NR'Rb, —NRIC(0)Rb, —NR•C(0)NRb, — NrC(0)0Rb, —SR', —S(0)1.2R', —S(0)2NR•R b, —NR'S(0)2Rb, CI. 6haloalkyl, C34cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, C640 aryl, and 5 to 10 membered heteroaryl wherein
2 18435
the 5 to 10 membered heteroaryl has Ito 3 heteroatoms selected from oxygen, nitrogen, and sulfur; wherein each C34cycloalkyl, 3 to 6 membered heterocyclyl, Cs-wary], and 5 to 10 membered heteroaryl is optionally substituted with 1 to 5 R 2' groups; RI° is selected from hydrogen, halogen, C14alkyl, CN, —NR'Rb, —S(0)1.2111, and OR*, wherein Cialkyl is optionally substituted with Ito 5 1t 2° groups each R2° is independently selected from the group consisting of halogen, CI. 6haloalkyl, CN, S(0)1.21V, and OR'; each R2' is independently selected from the group consisting of halogen, CI. 6alkyl, Ci4haloalkyl, CN, —NR'Rb, S(0)1.2r, and OR'; and each Rs and Rb are independently selected from the group consisting of hydrogen and CI4alkyl; wherein each CI.6alkyl is optionally substituted with Ito 5 substituents independently selected from halogen, hydroxyl, amino, 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, and CI. 6haloalkyl; provided that when X is N, R' is Cl, R2 is H and R3 is H then R4 is not CH2CH20Me or CH2CH2S02Me. 100071 The present disclosure provides a compound of Formula (I):
R4 NH
or a pharmaceutically acceptable salt thereof, wherein: RI is selected from the group consisting of hydrogen, halogen, C14alkyl, CN, — NR*Rb, —S(0)1.21V, and OR', wherein C14alkyl is optionally substituted with Ito 5 R2° groups; R2 is selected from the group consisting of hydrogen, halogen, C14alkyl, CN, —S(0)1.2R1 and OR', wherein Chsalkyl is optionally substituted with Ito 5 R2° groups;
3 18435
R3 is selected from the group consisting of hydrogen, halogen, CI-alkyl, CN, — NR'Rb, —S(0)1-2R', and ORI, wherein CI-alkyl is optionally substituted with 1 to 5 R2° groups;
it is C1-12 alkyl which is optionally substituted with Ito 5 substituents independently selected from halogen, -OR', CN, —C(0)111, — C(0)01V, —C(0)NR*Rb, —0C(0)NRIRb, —NIVC(0)Rb, —NR2C(0)NRb, — NRIC(0)01e, —SR', —S(0)1.2R', —S(0)2NR 1Rb, —NR'S(0)2Rb, CI. 6haloalkyl, C3_6cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, C6.10 aryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has Ito 3 heteroatoms selected from oxygen, nitrogen, and sulfur;
wherein each C3.6cycloalkyl, 3 to 6 membered heterocyclyl, C6-10 aryl, and 5 to 10 membered heteroaryl is optionally substituted with Ito 5 R 2 ' groups; each R2° is independently selected from the group consisting of halogen, CI. shaloalkyl, CN, —NR'Rb, S(0)1.2R', and OR'; each R2 ' is independently selected from the group consisting of halogen, CI. 6alkyl, C1.6haloalkyl, CN, —NR'Rb, S(0)1.2W, and OR'; and each R' and Rb are independently selected from the group consisting of hydrogen and CI-alkyl; wherein each CI.alkyl is optionally substituted with 1 to 5 substituents independently selected from halogen, hydroxyl, amino, 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, and 6haloalkyl; provided that when R' is Cl, R2 is H and R3 is H then R's is not CH2CH20Me or CH2CH2S02Me. 10008/ The present disclosure provides a compound of Formula (IV):
R13 R" YR12 HN
R3
Formula (IV) '
4 18435 wherein:
IV is selected from the group consisting of hydrogen, halogen, CI.6 alkyl, CN, and OW, wherein C1.6 alkyl is optionally substituted with 1 to 5 R 2° groups; R2 is selected from the group consisting of hydrogen, halogen, Ci-is alkyl, CN, and OR', wherein C2.6 alkyl optionally substituted with 1 to 5 R 2° groups;
113 is selected from the group consisting of hydrogen, halogen, C14 alkyl, CN, and OR', wherein C1.6 alkyl is optionally substituted with I to 5 R 2° groups; R11 is selected from the group consisting of C1_2 alkyl, C3.6 cycloallcyl, and C13 haloalkyl; R12 is selected from C1.3 alkyl, halogen, -OR', CN, —C(0)IV, —C(0)01V, —C(0)NR'R1', —0C(0)NR'Rb, —NIVC(0)Rb, —NR'C(0)NRb, — NR1C(0)0Rb, —SR', —S(0)1-212,, —S(0)2NIVEtb, —NR'S(0)2Rb, C1.3 haloalkyl, C3-s cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has I to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, Cs.maryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has Ito 3 heteroatoms selected from
oxygen, nitrogen, and sulfur, wherein the CI.3 alkyl group is optionally substituted with 1 or 2 substituents independently selected from halogen, - OR', —NR'Rb, CN, —C(0)IV, —C(0)011', —C(0)NR'Rb, —0C(0)NRIRb, — NR1C(0)Rb, —NRIC(0)NRb, —NRIC(0)0Rb, —SR', —S(0)1.2124, — S(0)2NR'Rb, —NR'S(0)2Rb, C1.3 haloalkyl, C34 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, Cs.loaryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur; R13 is selected from Cbs alkyl, halogen, -OR', —NR'R b, CN, —C(0)111, —C(0)011', —C(0)NIVIe, —0C(0)NIVIt b, —NRIC(0)Rb, —NRIC(0)NRb, — NIVC(0)0Rb, —SR', —S(0)1.21e, —S(0)2NIVIlb, —NR'S(0)2Rb, C1-6
haloalkyl, C34 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, Cs-loaryl, and 5 to 10 membered heteroaryl wherein
5 18435
the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, wherein the C14 alkyl is optionally substituted with 1 to 2 substituents independently selected from halogen, - OR', —NR'Rb, CN, —C(0)R', —C(0)011.1, —C(0)NR'Rb, —0C(0)NR'llb, — NRIC(0)Rb, —NR•C(0)NRb, —NR1C(0)0Rb, —SR', —S(0)141V, — S(0)2NR'Rb, —NR'S(0)2Rb, C1-6 haloalkyl, C34 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has I to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, Cs-lo aryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur; each R" is independently selected from the group consisting of halogen, CN, — NIrltb, and OR'; and each 1r and Rb is independently selected from the group consisting of hydrogen and Ci4 alkyl, wherein each C1-3 alkyl is optionally substituted with Ito 3 substituents independently selected from halogen, -OH, and NH2. 100091 In certain embodiments, the present disclosure provides a pharmaceutical composition comprising a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition comprises one or more additional therapeutic agents.
100101 In certain embodiments, a method of modulating TLR-8 is provided, comprising administering a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, to an individual (e.g. a human).
100111 In certain embodiments, a method of treating or preventing a disease or condition responsive to the modulation of TLR-8 is provided, comprising administering to an individual (e.g. a human) in need thereof a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. In certain embodiments, the method of treating or preventing a disease or condition responsive to the modulation of TLR-8, comprises administering one or more additional therapeutic agents.
6 18435
[0012] In certain embodiments, a method of treating or preventing a viral infection is provided, comprising administering to an individual (e.g. a human) in need thereof a therapeutically effective amount a compound of the present disclosure, or a pharmaceutically acceptable salt thereof.
[0013] In certain embodiments, a method of treating or preventing a hepatitis B viral infection is provided, comprising administering to an individual (e.g. a human) in need thereof a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. In certain embodiments, the method of treating or preventing a hepatitis B viral infection comprises administering one or more additional therapeutic agents. In certain embodiments, the individual is a human infected with hepatitis B.
[0014] In certain embodiments, a method of treating or preventing a HIV infection is provided, comprising administering to an individual (e.g. a human) in thereof a therapeutically effective amount a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. In certain embodiments, the method of treating or preventing a HIV infection comprises administering one or more additional therapeutic agents. In certain embodiments, the individual is a human infected with HIV (e.g. HIV-1).
100151 In certain embodiments, a method of treating a hyperproliferative disease (e.g. cancer) is provided, comprising administering to an individual (e.g. a human) in thereof a therapeutically effective amount a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. In certain embodiments, the method of treating a hyperproliferative disease (e.g. cancer) comprises administering one or more additional therapeutic agents. In certain embodiments, the individual is a human.
100161 In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in medical therapy is provided.
[0017] In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a disease or condition responsive to the modulation of TLR-8, is provided In certain embodiments, the disease or condition is a viral infection.
7 18435
100181 In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in treating or preventing hepatitis B, is provided
100191 In certain embodiments, the use of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating or preventing a disease or condition responsive to the modulation of TLR-8, is provided.
100201 In certain embodiments, the use of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating or preventing hepatitis B, is provided.
100211 Kits comprising the compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions of the foregoing are also provided. Articles of manufacture comprising a unit dose of the compounds, or pharmaceutically acceptable salts thereof, of the foregoing are also provided. Methods of preparing compounds of the present disclosure are also provided.
DETAILED DESCRIPTION
100221 The description below is made with the understanding that the present disclosure is to be considered as an exemplification of the claimed subject matter, and is not intended to limit the appended claims to the specific embodiments illustrated. The headings used throughout this disclosure are provided for convenience and are not to be construed to limit the claims in any way. Embodiments illustrated under any heading may be combined with embodiments illustrated under any other heading.
I. DEFINITIONS
100231 Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. A dash at the front or end of a chemical group is a matter of convenience to indicate the point of attachment to a parent moiety; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. A prefix such as "C..,," or (C.-C) indicates that the following group has from u to v carbon atoms, where u and v are integers. For example, "C14alkyl" indicates that the alkyl group has from I to 6 carbon
atoms.
8 18435
100241 "Alkyl" is a linear or branched saturated monovalent hydrocarbon. For example, an alkyl group can have Ito 10 carbon atoms (i e., (C1.10)alkyl) or Ito 8 carbon atoms (i.e., (C1-8)alkyl) or Ito 6 carbon atoms (i.e., (C14 alkyl) or Ito 4 carbon atoms (i.e., (C14alkyl). Examples of alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CH2CH3), 2-propyl (1- Pr, i-propyl, -CH(CH3)2), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl-l-propyl (i-Bu, i-butyl, -CH2CH(CH3)2), 2-butyl (s-13u, s-butyl, -CH(CH3)CH2C113), 2-methy1-2- propyl (1-Bu, 1-butyl, -C(CH)3), 1-pentyl (n-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2C113), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH))CH(CH3)2), 3-methyl-l-butyl (-CH2CH2CH(CH3)2), 2-methyl-l-butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(0-13)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethy1-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethy1-2-butyl (-01(CH))C(CH3)3, and octyl (-(CH2)7CH3).
100251 "Alkenyl" is a linear or branched monovalent hydrocarbon radical with at least one carbon-carbon double bond. For example, an alkenyl group can have 2 to 8 carbon atoms (i.e., C2-8 alkenyl), or 2 to 6 carbon atoms (i.e., C2.6 alkenyl) or 2 to 4 carbon atoms (i e., C24 alkenyl). Examples of suitable alkenyl groups include, but are not limited to, ethylene or vinyl (-CH=C112), allyl (-CH2CH=CH2), 5-hexenyl (-CH2CH2CH2CH2CH=CH2), and 3-hexenyl (-CH2CH2CH-CHCH2CH2).
100261 "Alkynyl" is a linear or branched monovalent hydrocarbon radical with at least one carbon-carbon triple bond. For example, an alkynyl group can have 2 to 8 carbon atoms (i.e., C23 alkyne,) or 2 to 6 carbon atoms (i.e., C2.6 alkynyl) or 2 to 4 carbon atoms (i e., C24 alkynyl). Examples of alkynyl groups include, but are not limited to, acetylenyl (-C=CH), propargyl (-012CECH), and -CH2-CEC-CH3. .
100271 The term "halo"or "halogen" as used herein refers to fluor° (-F), chloro (-Cl), bromo (-Br) and iodo (-I)
100281 The term "haloalkyl" as used herein refers to an alkyl as defined herein, wherein one or more hydrogen atoms of the alkyl are independently replaced by a halo
9 18435 substituent, which may be the same or different. For example, CI-shaloalkyl is a Ci. alkyl wherein one or more of the hydrogen atoms of the Cbsalkyl have been replaced by a halo substituent. Examples of haloalkyl groups include but are not limited to fluoromethyl, fluorochloromethyl, difluoromethyl, difluorochloromethyl, trifluoromethyl, 1,1,1-trifluoroethyl and pentafluoroethyl.
100291 The term "heteroalkyl" as used herein refers to an alkyl as defined herein, wherein one or more of the carbon atoms of the alkyl are replaced by an 0, S, or NIV, wherein each WI is independently H or Cl.alkyl. For example, Cl.sheteroalkyl intends a heteroalkyl of one to eight carbons wherein one or more carbon atoms is replaced by a heteroatom (e.g., 0, S, OH, SH or N(R)2), which may the same or different. Examples of heteroalkyls include but are not limited to methoxymethyl, ethoxymethyl, methoxy, 2-hydroxyethyl and N,N'-dimethylpropylamine. A heteroatom of a heteroalkyl may optionally be oxidized or alkylated. A heteroatom may be placed at any interior position of the heteroalkyl group or at a position at which the group is attached to the remainder of the molecule. Examples include, but are not limited to, -CH2OCH3, - CH2CH2NHCH3, -CH2CH2N(CH3) -CH3, -CH2SCH2CH3, -S(0)CH3. - CH2CH2S(0)2C1-13, -CHCHOCH3, -CH2CHNOCH3, -CHCHN(CH3)C113,- CH2NHOCH3 and -CH20S(CH3)3
100301 The term "aryl" as used herein refers to a single all carbon aromatic ring or a multiple condensed all carbon ring system wherein at least one of the rings is aromatic. For example, in certain embodiments, an aryl group has 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 12 carbon atoms. Aryl includes a phenyl radical. Aryl also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) having about 9 to 20 carbon atoms in which at least one ring is aromatic and wherein the other rings may be aromatic or not aromatic (i.e., carbocycle). Such multiple condensed ring systems are optionally substituted with one or more (e.g., 1, 2 or 3) oxo groups on any carbocycle portion of the multiple condensed ring system. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is also to be understood that when reference is made to a certain atom-range membered aryl (e.g., 6-10 membered aryl), the atom range is for the total ring atoms of the aryl. For example, a 6-membered aryl would include phenyl and a 10-membered aryl would include naphthyl and 1, 2, 3, 4-tetrahydronaphthyl.
10 18435
Non-limiting examples of aryl groups include, but are not limited to, phenyl, indenyl, naphthyl, 1, 2, 3, 4-tetrahydronaphthyl, anthracenyl, and the like.
(00311 The term "heteroaryl" as used herein refers to a single aromatic ring that has at least one atom other than carbon in the ring, wherein the atom is selected from the group consisting of oxygen, nitrogen and sulfur; "heteroaryl" also includes multiple condensed ring systems that have at least one such aromatic ring, which multiple condensed ring systems are further described below. Thus, "heteroaryl" includes single aromatic rings of from about 1 to 6 carbon atoms and about 1-4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur. The sulfur and nitrogen atoms may also be present in an oxidized form provided the ring is aromatic. Exemplary heteroaryl ring systems include but are not limited to pyridyl, pyrimidinyl, oxazolyl or furyl. "Heteroaryl" also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) wherein a heteroaryl group, as defined above, is condensed with one or more rings selected from heteroaryls (to form for example 1,8- naphthyridinyl), heterocycles, (to form for example 1,2,3,4-tetrahydro-1,8- naphthyridinyl), carbocycles (to form for example 5,6,7,8-tetrahydroquinoly1) and aryls (to form for example indazoly1) to form the multiple condensed ring system. Thus, a heteroaryl (a single aromatic ring or multiple condensed ring system) has about 1-20 carbon atoms and about 1-6 heteroatoms within the heteroaryl ring. Such multiple condensed ring systems may be optionally substituted with one or more (e.g., 1, 2, 3 or 4) oxo groups on the carbocycle or heterocycle portions of the condensed ring. The rings of the multiple condensed ring system can be connected to each other via fused, Spiro and bridged bonds when allowed by valency requirements. It is to be understood that the individual rings of the multiple condensed ring system may be connected in any order relative to one another. It is to be understood that the point of attachment for a heteroaryl or heteroaryl multiple condensed ring system can be at any suitable atom of the heteroaryl or heteroaryl multiple condensed ring system including a carbon atom and a heteroatom (e.g., a nitrogen). It also to be understood that when a reference is made to a certain atom-range membered heteroaryl (e.g., a 5 to 10 membered heteroaryl), the atom range is for the total ring atoms of the heteroaryl and includes carbon atoms and heteroatoms. For example, a 5-membered heteroaryl would include a thiazolyl and a 10- membered heteroaryl would include a quinolinyl. Exemplary heteroaryls include but are not limited to pyridyl, pyffolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl,
11 18435 indolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxalyl, quinazolyl, 5,6,7,8-tetrahydroisoquinolinyl benzofuranyl, benzimidazolyl, thianaphthenyl, pyrrolo[2,3-b]pyridinyl, quinazoliny1-4(3H)-one, triazolyl, 4,5,6,7-tetrahydro-111- indazole and 313,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole.
(0032] The term "cycloalkyl" refers to a single saturated or partially unsaturated all carbon ring having 3 to 20 annular carbon atoms (i.e., C3.20 cycloalkyl), for example from 3 to 12 annular atoms, for example from 3 to 10 annular atoms. The term "cycloalkyl" also includes multiple condensed, saturated and partially unsaturated all carbon ring systems (e.g., ring systems comprising 2, 3 or 4 carbocyclic rings). Accordingly, cycloalkyl includes multicyclic carbocyles such as a bicyclic carbocycles (e.g , bicyclic carbocycles having about 6 to 12 annular carbon atoms such as bicyclo[3.1.0Thexane and bicyclo[2.1.1Thexane), and polycyclic carbocycles (e.g tricyclic and tetracyclic carbocycles with up to about 20 annular carbon atoms). The rings of a multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. Non-limiting examples of monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2- enyl and 1-cyclohex-3-enyl.
100331 The term "heterocycly1" or "heterocycle" as used herein refers to a single saturated or partially unsaturated non-aromatic ring or a non-aromatic multiple ring system that has at least one heteroatom in the ring (i.e., at least one annular heteroatom selected from oxygen, nitrogen, and sulfur) Unless otherwise specified, a heterocyclyl group has from 5 to about 20 annular atoms, for example from 3 to 12 annular atoms, for example from 5 to 10 annular atoms. Thus, the term includes single saturated or partially unsaturated rings (e.g , 3, 4, 5, 6 or 7-membered rings) having from about 1 to 6 annular carbon atoms and from about 1 to 3 annular heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the ring. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. Heterocycles include, but are not limited to, azetidine, aziridine, imidazolidine, morpholine, oxirane (epoxide), oxetane, piperazine, piperidine, pyrazolidine, piperidine, pyrrolidine, pyrrolidinone, tetrahydrofuran, 12 f 18435 tetrahydrothiophene, dihydropyridine, tetrahydropyridine, quinuclidine, N- bromopyrrolidine, N-chloropiperidine, and the like.
100341 The term "oxo" as used herein refers to =0.
[00351 As used herein, "treatment" or "treating" is an approach for obtaining beneficial or desired results. For purposes of the present disclosure, beneficial or desired results include, but are not limited to, alleviation of a symptom and/or diminishment of the extent of a symptom and/or preventing a worsening of a symptom associated with a disease or condition. In one embodiment, "treatment" or "treating" includes one or more of the following: a) inhibiting the disease or condition (e.g., decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); b) slowing or arresting the development of one or more symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, delaying the worsening or progression of the disease or condition); and c) relieving the disease or condition, e.g., causing the regression of clinical symptoms, ameliorating the disease state, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival.
100361 A "compound of the present disclosure" includes compounds disclosed herein, for example a compound of the present disclosure includes compounds of Formula (J), (I), (Ia), (lb), (11), (Ha), (11b), (III), (111a), (111b), and the compounds listed in Table 1. A compound of the present disclosure also includes compounds of Formula (J), (I), (la), (lb), (II), (Ha), (lib), (III), (111a), (111b), (VI), (IVa), (IVb), (IVc), (1Vd), the compounds of Examples 1-113, and the compounds listed in Tables 1 and 3. A compound of the present disclosure also includes the compounds of Examples 1-118
100371 As used herein, "delaying" development of a disease or condition means to defer, hinder, slow, retard, stabilize and/or postpone development of the disease or condition. This delay can be of varying lengths of time, depending on the history of the disease and/or individual being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop the disease or condition. For example, a method that "delays" development of AIDS is a method that reduces the probability of disease development in a given time frame and/or reduces extent of the disease in a given time frame, when compared to not using the method. Such comparisons may be based on clinical studies,
13 18435 using a statistically significant number of subjects. For example, the development of AIDS can be detected using known methods, such as confirming an individual's HIV+ status and assessing the individual's T-cell count or other indication of AIDS development, such as extreme fatigue, weight loss, persistent diarrhea, high fever, swollen lymph nodes in the neck, armpits or groin, or presence of an opportunistic condition that is known to be associated with AIDS (e.g., a condition that is generally not present in individuals with functioning immune systems but does occur in AIDS patients). Development may also refer to disease progression that may be initially undetectable and includes occurrence, recurrence and onset.
[00381 As used herein, "prevention" or "preventing" refers to a regimen that protects against the onset of the disease or disorder such that the clinical symptoms of the disease do not develop. Thus, "prevention" relates to administration of a therapy (e.g , administration of a therapeutic substance) to a subject before signs of the disease are detectable in the subject (e.g., administration of a therapeutic substance to a subject in the absence of detectable infectious agent (e.g., virus) in the subject). The subject may be an individual at risk of developing the disease or disorder, such as an individual who has one or more risk factors known to be associated with development or onset of the disease or disorder. Thus, in certain embodiments, the term "preventing HBV infection" refers to administering to a subject who does not have a detectable HBV infection an anti-HBV therapeutic substance. It is understood that the subject for anti-HBV preventative therapy may be an individual at risk of contracting the HBV virus. Thus, in certain embodiments, the term "preventing HIV infection" refers to administering to a subject who does not have a detectable HIV infection an anti-HIV therapeutic substance. It is understood that the subject for anti-HIV preventative therapy may be an individual at risk of contracting the HIV virus.
[0039] As used herein, an "at risk" individual is an individual who is at risk of developing a condition to be treated. An individual "at risk" may or may not have detectable disease or condition, and may or may not have displayed detectable disease prior to the treatment of methods described herein. "At risk" denotes that an individual has one or more so-called risk factors, which are measurable parameters that correlate with development of a disease or condition and are known in the art. An individual having one or more of these risk factors has a higher probability of developing the
14 18435
disease or condition than an individual without these risk factor(s). For example, individuals at risk for AIDS are those having HIV.
100401 As used herein, the term "therapeutically effective amount" or "effective amount" refers to an amount that is effective to elicit the desired biological or medical response, including the amount of a compound that, when administered to a subject for treating a disease, is sufficient to effect such treatment for the disease. The effective amount will vary depending on the compound, the disease, and its severity and the age, weight, etc., of the subject to be treated. The effective amount can include a range of amounts. As is understood in the art, an effective amount may be in one or more doses, I.e., a single dose or multiple doses may be required to achieve the desired treatment endpoint. An effective amount may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable or beneficial result may be or is achieved. Suitable doses of any co-administered compounds may optionally be lowered due to the combined action (e.g., additive or synergistic effects) of the compounds.
00411 As used herein, an "agonist" is a substance that stimulates its binding partner, typically a receptor. Stimulation is defined in the context of the particular assay, or may be apparent in the literature from a discussion herein that makes a comparison to a factor or substance that is accepted as an "agonist" or an "antagonist" of the particular binding partner under substantially similar circumstances as appreciated by those of skill in the art. Stimulation may be defined with respect to an increase in a particular effect or function that is induced by interaction of the agonist or partial agonist with a binding partner and can include allosteric effects.
[0042] As used herein, an "antagonist" is a substance that inhibits its binding partner, typically a receptor. Inhibition is defined in the context of the particular assay, or may be apparent in the literature from a discussion herein that makes a comparison to a factor or substance that is accepted as an "agonist" or an "antagonist" of the particular binding partner under substantially similar circumstances as appreciated by those of skill in the art Inhibition may be defined with respect to a decrease in a particular effect or function that is induced by interaction of the antagonist with a binding partner, and can include allosteric effects.
15 18435
[0043] As used herein, a "partial agonist" or a "partial antagonist" is a substance that provides a level of stimulation or inhibition, respectively, to its binding partner that is not fully or completely agonistic or antagonistic, respectively. It will be recognized that stimulation, and hence, inhibition is defined intrinsically for any substance or category of substances to be defined as agonists, antagonists, or partial agonists.
[0044] As used herein, "intrinsic activity" or "efficacy" relates to some measure of biological effectiveness of the binding partner complex. With regard to receptor pharmacology, the context in which intrinsic activity or efficacy should be defined will depend on the context of the binding partner (e.g., receptor/ligand) complex and the consideration of an activity relevant to a particular biological outcome. For example, in some circumstances, intrinsic activity may vary depending on the particular second messenger system involved. Where such contextually specific evaluations are relevant, and how they might be relevant in the context of the present disclosure, will be apparent to one of ordinary skill in the art.
[0045] "Pharmaceutically acceptable excipient" includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals
[0046] As used herein, modulation of a receptor includes agonism, partial agonism, antagonism, partial antagonism, or inverse agonism of a receptor.
100471 The nomenclature used herein to name the subject compounds is illustrated in the Examples and elsewhere herein.
100481 As used herein, "co-administration" includes administration of unit dosages of the compounds disclosed herein before or after administration of unit dosages of one or more additional therapeutic agents, for example, administration of the compound disclosed herein within seconds, minutes, or hours of the administration of one or more additional therapeutic agents. For example, in some embodiments, a unit dose of a compound of the present disclosure is administered first, followed within seconds or minutes by administration of a unit dose of one or more additional therapeutic agents. Alternatively, in other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a compound of
16 18435
the present disclosure within seconds or minutes. In some embodiments, a unit dose of a compound of the present disclosure is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of one or more additional therapeutic agents. In other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of a compound of the present disclosure.
100491 Provided are also pharmaceutically acceptable salts, hydrates, solvates, tautomeric forms, polymorphs, and prodrugs of the compounds described herein. "Pharmaceutically acceptable" or "physiologically acceptable" refer to compounds, salts, compositions, dosage forms and other materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use.
[0050] The compounds of described herein may be prepared and/or formulated as pharmaceutically acceptable salts. Pharmaceutically acceptable salts are non-toxic salts of a free base form of a compound that possesses the desired pharmacological activity of the free base. These salts may be derived from inorganic or organic acids or bases. For example, a compound that contains a basic nitrogen may be prepared as a pharmaceutically acceptable salt by contacting the compound with an inorganic or organic acid. Non-limiting examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen- phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-I,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, methylsulfonates, propylsulfonates, besylates, xylenesulfonates, naphthalene-l-sulfonates, naphthalene-2-sulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, y-hydroxybutyrates, glycolates, tartrates, and mandelates. Lists of other suitable pharmaceutically acceptable salts are found in Remington: The Science and Practice of Pharmacy, 21" Edition, Lippincott Wiliams and Wilkins, Philadelphia, Pa., 2006.
[0051] Examples of "pharmaceutically acceptable salts" of the compounds disclosed herein also include salts derived from an appropriate base, such as an alkali metal (for
17 18435
example, sodium, potassium), an alkaline earth metal (for example, magnesium), ammonium and NX4+ (wherein X is Ci—C4 alkyl) Also included are base addition salts, such as sodium or potassium salts.
100521 Provided are also compounds described herein or pharmaceutically acceptable salts, isomers, or a mixture thereof, in which from 1 to n hydrogen atoms attached to a carbon atom may be replaced by a deuterium atom or D, in which n is the number of hydrogen atoms in the molecule. As known in the art, the deuterium atom is a non- radioactive isotope of the hydrogen atom. Such compounds may increase resistance to metabolism, and thus may be useful for increasing the half-life of the compounds described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof when administered to a mammal. See, e.g., Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism", Trends Pharmacol. Sci., 5(I2):524-527 (1984). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogen atoms have been replaced by deuterium.
100531 Examples of isotopes that can be incorporated into the disclosed compounds also include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, 2H , 3H , tic, 13c, 14C, 13N, 15N, 150, 170, 180, 31p, 32p, 35^ , and iodine, such as 18F, 36Cl,
123 1, and 1251, respectively. Substitution with positron emitting isotopes, such as "C, 15F, "0 and "N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled compounds of Formula (I), can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Examples as set out below using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
100541 The compounds of the embodiments disclosed herein, or their pharmaceutically acceptable salts may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids. The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-), (1?)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization.
18 18435
Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centres of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.
[0055] A "stereoisomer" refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The present disclosure contemplates various stereoisomers and mixtures thereof and includes "enantiomers", which refers to two stereoisomers whose molecules are non-superimposable mirror images of one another.
[0056] A "tautomer" refers to a proton shift from one atom of a molecule to another atom of the same molecule. The present disclosure includes tautomers of any said compounds.
[0057] A "solvate" is formed by the interaction of a solvent and a compound. Solvates of salts of the compounds described herein are also provided. Hydrates of the compounds described herein are also provided.
[0058] A "prodrug" includes any compound that becomes a compound described herein when administered to a subject, e.g., upon metabolic processing of the prodrug.
[0059] The terms "combination antiretroviral therapy" ("cART") refers to combinations or "cocktails" of antiretroviral medications used to treat human viral infections, including HIV infections. As used herein, the terms "combination antiretroviral therapy" and "cART include combinations and regimens often referred to as Highly Active Antiretroviral Therapy (HAART). HAART and cART combinations and regimens commonly include multiple, often two or more, drugs such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (Pis), fusion inhibitors, CCR5 agonists, and/or integrase inhibitors.
[0060] The terms "latent HIV reservoir", " HIV latent reservoir", "HIV reservoir", "latent reservoir", and "latent HIV infection" refer to a condition in which resting CD4+
19 18435
T lymphocytes or other cells are infected with HIV but are not actively producing HIV. The presently inactive HIV infected cells are referred to as "latently infected cells". Antiretroviral therapy (ART) can reduce the level of HIV in the blood to an undetectable level, while latent reservoirs of HIV continue to survive. When a latently infected cell is reactivated, the cell begins to produce HIV (HIV replication).
H. COMPOUNDS
100611 The present disclosure provides a compound of Formula (J):
R4 NH
R2 N NH2 R3 (0 or a pharmaceutically acceptable salt thereof, wherein: X is N or CRI °; RI is selected from the group consisting of hydrogen, halogen, Cbsalkyl, CN, — NR'Rb, —S(0)1-2R', and OR', wherein Cbalkyl is optionally substituted with 1 to 5 R2° groups; R2 is selected from the group consisting of hydrogen, halogen, Cbalkyl, CN, psb —S(0)1.212' and OR', wherein Cbalkyl is optionally substituted with 1 to 5 R2° groups; R3 is selected from the group consisting of hydrogen, halogen, Cbalkyl, CN, — NR'Rb, —S(0)1.2R*, and OR', wherein Cialkyl is optionally substituted with Ito 5 R2° groups; Its is Cb12 alkyl which is optionally substituted with I to 5 substituents independently selected from halogen, -OR', —NR'R b, CN, —C(0)12*, — C(0)0111, —C(0)NR*Rb, —0C(0)NR'Rb, —NIVC(0)Rb, —NR1C(0)NRb, — NR"C(0)0Rb, —SR', —S(0)1.2111, —S(0)2NR'Rb, —NR'S(0)2Rb, Ci- shaloalkyl, Cmcycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, Cs.loaryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has I to 3 heteroatoms selected from oxygen, nitrogen, and sulfur;
20 18435
wherein each C3.6cycloalkyl, 3 to 6 membered heterocyclyl, C6.10 aryl, and 5 to 10 membered heteroaryl is optionally substituted with I to 5 R 21 groups; RI° is selected from hydrogen, halogen, CI.6alkyl, CN, —S(0)1.21V, and OR', wherein CI-alkyl is optionally substituted with 1 to 5 R2° groups each R2° is independently selected from the group consisting of halogen, CI. 6haloalkyl, CN, —NR'Rb, S(0)1.2R1, and OR'; each R2I is independently selected from the group consisting of halogen, CI. 6alkyl, CI4haloalkyl, CN, —NR'Rb, S(0)1.2R 1, and OR'; and each R' and Rb are independently selected from the group consisting of hydrogen and Ct-alkyl; wherein each Cialkyl is optionally substituted with I to 5 substituents independently selected from halogen, hydroxyl, amino, 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, and CI. 6haloalkyl; provided that when X is N, RI is Cl, R2 is H and IV is H then 114 is not CH2CH20Me or CH2CH2S02Me. 100621 In certain embodiments of Formula (J), Xis CRI°. In certain embodiments of Formula (J), X is N.
(00631 The present disclosure provides a compound of Formula (I) .
R4 NH
or a pharmaceutically acceptable salt thereof, wherein: RI is selected from the group consisting of hydrogen, halogen, C1-6alkyl, CN, — NR'Rb, —S(0)1.2R1, and OR', wherein Cialkyl is optionally substituted with I to 5 R2° groups; R2 is selected from the group consisting of hydrogen, halogen, Ci.6alkyl, CN, — NR'Rb, —S(0)1.21V and OR', wherein CI-alkyl is optionally substituted with I to 5 R2° groups;
21 18435
R3 is selected from the group consisting of hydrogen, halogen, Ct.6alkyl, CN, — NR'Rb, —S(0)1-211", and OR', wherein Ct4alkyl is optionally substituted with Ito 5 R2° groups; It' is C1-12 alkyl which is optionally substituted with 1 to 5 substituents independently selected from halogen, -OR', CN, —C(0)11*, — C(0)0111, —C(0)NRIftb, —0C(0)NRIRb, —NR1C(0)Rb, —NRIC(0)N1kbe — NIVC(0)0Rb, —SR', —S(0)1.2R", —S(0)2N12.92b, —NR'S(0)2Rb, C1- 6haloalkyl, C34cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has Ito 3 heteroatoms selected from oxygen, nitrogen, and sulfur, CE-toaryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has Ito 3 heteroatoms selected from oxygen, nitrogen, and sulfur; wherein each C34cycloalkyl, 3 to 6 membered heterocyclyl, C6.to aryl, and 5 to 10 membered heteroaryl is optionally substituted with 1 to 5 R 2' groups; each R2° is independently selected from the group consisting of halogen, Ct. 6haloalkyl, CN, S(0)1.21V, and Or; each R2' is independently selected from the group consisting of halogen, CI. CN, —NR'Rb, S(0)1.21V, and OR'; and each Wand RI' are independently selected from the group consisting of H and CI. (alkyl, wherein each CI-alkyl is optionally substituted with 1 to 5 substituents independently selected from halogen, hydroxyl, amino, 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, and Ct. 6haloalkyl; provided that when R' is Cl, R2 is H and IV is H then R4 is not CH2CI120Me or CH2CH2S02Me. [0064] In certain embodiments of a compound of Formula (J) or (I), R 4 is C14 alkyl which is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, -OR', CN, —C(0)1111, —C(0)0r, — 0C(0)NR•R1', —NIVC(0)Rb, —NRT(0)NRb, —NWC(0)0Rb, —S(0)1.2111, — S(0)2NR*Rb, —NR'S(0)2Rb, Ci4haloalkyl, C34cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, C6-10 aryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur;
22 18435 and wherein each C3.6cycloalkyl, 3 to 6 membered heterocyclyl, C6-10 aryl, and 5 to 10 membered heteroaryl is optionally substituted with 1 to 5 R21 groups.
(0065] In certain embodiments of a compound of Formula (J) or (1), le is C14 alkyl optionally substituted with 1 to 5 substituents independently selected from the group 5 consisting of halogen, -OR', —C(0)01V, —C(0)NR'R b,—SR , Cj4haloalkyl , C3- scycloalkyl, 3 to 6 membered heterocyclyl, and C6-to aryl; wherein each C3.6cycloalkyl, 3 to 6 membered heterocyclyl, and C6.10 aryl is optionally substituted with 1 to 5 R 21 groups. In certain embodiments of a compound of Formula (J) or (I), le is C34 alkyl optionally substituted with I to 5 substituents independently selected from the group consisting of halogen, -OR', —C(0)01V, —NR 1C(0)Rb,—SR', CI4haloalkyl, C3. scycloalkyl, 3 to 6 membered heterocyclyl, and C6-10 aryl; wherein each C34cycloalkyl, 3 to 6 membered heterocyclyl, and C6.10 aryl is optionally substituted with Ito 5 R 21 groups.
100661 In certain embodiments of a compound of Formula (J) or (I), R4 is C1.6 alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, -OR', —C(0)011*, —C(0)NR 1Rb, —SR', —C1.3haloalkyl, C3-
6cycloalkyl, 3 to 6 membered heterocyclyl and C6-10 aryl; wherein each C34cycloalkyl and C6-10 aryl is optionally substituted with Ito 3 R21 groups. In certain embodiments of a compound of Formula (J) or (I), R4 1s C3-8 alkyl optionally substituted with I to 3 substituents independently selected from the group consisting of halogen, -OR', — C(0)0111, —NR1C(0)Rb, —SR', —C14haloalkyl, C3.6cycloalkyl, 3 to 6 membered heterocycly1 and C6-to aryl; wherein each C34cycloalkyl and C6-10 aryl is optionally substituted with I to 3 R21 groups.
100671 In certain embodiments of a compound of Formula (J) or (I), R 4 is C14 alkyl optionally substituted with I or 2 substituents independently selected halogen, -OR', — C(0)0114, —C(0)NR*Rb, —SR', Ct.3haloalkyl, C3.6cycloalkyl, 3 to 6 membered heterocyclyl and C6.10 aryl; wherein each C34cycloalkyl and C6.10 aryl is optionally substituted with I to 3 R21 groups and wherein R' and R b are each independently hydrogen or CI-alkyl, wherein the CIA alkyl is optionally substituted with —NH2, OH, or pyridyl. In certain embodiments of a compound of Formula (J) or (I), R4 is C3-8 alkyl which is optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, -OR', —C(0)OR', —NR'C(0)R b, —SR', C1.3haloalkyl, C3-
23 18435 scycloalkyl, 3 to 6 membered heterocyclyl and C6.10 aryl; wherein each C34cycloalkyl and C6-11) aryl is optionally substituted with 1 to 3 R 2° groups and wherein R' and Rb are each independently hydrogen or Cialkyl, wherein each Clat alkyl is optionally substituted with –NH2, OH, or pyridyl.
[00681 In certain embodiments of a compound of Formula (J) or (I), 11 4 is C1.6 alkyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of OH, CF3,–C(0)0H, –C(0)0CH3, –C(0)N112, SCH3, –C(0)NHCH3, – C(0)NHCH2CH2NH2, –C(0)NHCH2CH2011, –C(0)NHCH2-pyridyl, phenyl, tetrahydrofuranyl, and cyclopropyl. In certain embodiments of a compound of Formula
(J) or (1), R4 is C3.8 alkyl which is optionally substituted with 1 or 2 substituents independently selected from OH, CF, –C(0)OH, –C(0)0CH3, SCH3, —NHC(0)CH3, – NHC(0)CH2CH2NH2, –NHC(0)CH2CH2OH, –NHC(0)CH2-pyridyl, phenyl, tetrahydrofuranyl, and cyclopropyl.
100691 In certain embodiments of a compound of Formula (J) or (I), R 4 is C3.6 alkyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of OH, CF3,–C(0)0H, –C(0)0CH3, –C(0)NH2, SCH3, –C(0)NHCH3, – C(0)NHCH2CH2NH2, –C(0)NHCH2CH2OH, and –C(0)NHCH2-pyridyl. In certain embodiments of a compound of Formula (J) or (I), 11 4 is C34 alkyl which is optionally substituted with 1 or 2 substituents independently selected from OH, CF3,–C(0)0H, – C(0)0CH3, SCH3, —NHC(0)CH3, –NHC(0)CH2CH2NH2, –NHC(0)CH2CH2OH, – NHC(0)CH2-pyridyl, phenyl, tetrahydrofuranyl, and cyclopropyl.
[00701 In certain embodiments of a compound of Formula (J) or (1), R 4 is Cl.salkyl which is optionally substituted with OH. In certain embodiments of a compound of
Formula (J) or (I), 114 is C3.6 alkyl which is optionally substituted with OH. In certain embodiments of a compound of Formula (J) or (I), R4 is C3.salkyl which is substituted with –NHC(0)CH3.
[0071] In certain embodiments of a compound of Formula (J) or (I), R 4 is C34 alkyl which is optionally substituted with OH. In certain embodiments of a compound of
Formula (J) or (I), R4 is C3-6 alkyl which is substituted with –NHC(0)CH3.
100721 In certain embodiments of a compound of Formula (J) or (I), R 4 has at least one chiral center. In certain embodiments, the at least one chiral center is in the S
24 18435 configuration. In certain embodiments, the at least one chiral center is in the R configuration.
[0073] In certain embodiments of a compound of Formula (J) or (I), R 4 is selected from the group consisting of:
F302 OH \CEvi . 3
OH g•y0 0
\CNC5 Ns/0:i
HO
NH Hi-OH
and ,....ir NH -....rNH2 H 0
[0074] In certain embodiments of a compound of Formula (J) or (I), R 4 is selected from the group consisting of:
25 18435
F3C ''...,„.0H PCF3
OH OH 0
L\Q...„....,OH \X0H N OH CI3 vCCt
HO
\,),...,,OH H..-..)1"-OH 0 0
Ns...... 11,NH ---," NH2 0 0
HN ...., In" 0 0
0H HIC>I ...1.."...%).....„...„ OH OH
yyNc 0I I \ 0I r V4- F F F
NH 0H ‘s. 1..,0Fi OH OH o
26
18435
F3C , v.y.-1 01-1 OH OH F
\\.. C;r1H
t■ F
and t.
100751 In certain embodiments of a compound of Formula (J) or (I), le is selected from the group consisting of:
F3C2 %'C'H
OH \INH2 OH
OH OH
HO N(1 .,.OH NH --.7--0H Hi-OH o o
_X)
NH-...."" NH2 NH --N o o
27
18435
4 )\--NH2
HC? OH OH OH
NH--r0H OH OH
H OH J.OH HNJ
OH CF3 and
100761 In certain embodiments of a compound of Formula (J) or (I), R 4 is selected from the group consisting of:
NH OH NH --....."' NI-12 0 o
100771 In certain embodiments of a compound of Formula (J) or (I), R 4 is selected from the group consisting of:
28
18435
NH-..0H Ns.,....,n, NH --..." NH2 0 o 0
N iNH ffi--N 0 and
100781 In certain embodiments of a compound of Formula (J) or (I), R 4 is selected from the group consisting of:
NH ...... r0H ‘‘...... 1.. NH -...... "" NH2 o 0 0
_X) NH "N 0
100791 In certain embodiments of a compound of Formula (I) or (I), les is selected from the group consisting of.
29 18435
OH H YC3
NH2 NH2
OH OH OH
;CON OH OH
NH OH
OH NH--rNH2 0
and NH --N NH2
100801 In certain embodiments of a compound of Formula (J) or (I), R4 is selected from the group consisting of
30
18435
F 3 C
N H 2
OH vt),
NH OH OH 0
NH L OH ,,. ....5, NH --....r" NH2 NH 0 0
OH NH2
NH --.."^-0H 0
OH OH OH OH OH OH
31
18435
F3C
OH OH OH HN-,1 HN-1/ V
OH
OH OH
F;... F and
(00811 In certain embodiments of a compound of Formula (J) or (I), le is selected from the group consisting of:
F3C')
'1/2. H \ C3
NH2 OH
OH OH
NH-,,r-OH N(0011 OH OH 0
5'5 NH-5-011 ,NH--7----NH2 NH —N 0 0
\"1
32
18435
F F
F .17.\LOH OH OH OH
NH-...7"--OH OH OH 0
F
OH OH
OH f 0082J In certain embodiments of a compound of Formula (J) or (I), R 4 is selected from the group consisting of:
NFI-...-----OH ■ „ iNH-_ "-NH2 o 0 0
,.‘ir ___ .. O \ NH --N \, NH--/--OH V Nr 0 0 0 and F.
100831 In certain embodiments of a compound of Formula (J) or (I), R4 is selected from the group consisting of:
33 18435
NH,r0H NH-_,-""NH2 0 0
\". 0
and [00841 In certain embodiments of a compound of Formula (J) or (I), R 4 is selected from the group consisting of:
,,O,F3 \\ COH . <.,OH OH OH
OH .s./ ...'''QCOH IND 0 and
(0085] In certain embodiments of a compound of Formula (J) or (I), R 4 is selected from the group consisting of.
OH OH .,OH r,,OH ,r 0H <,.OH 34 18435 It`O 0 and 100861 In certain embodiments of a compound of Formula (J) or (I), R 4 is selected from the group consisting or OH • OH OH H OH H 11'0 u and 0 100871 In certain embodiments of a compound of Formula (J) or (I), Ft ° is selected from the group consisting of. OH OH ' OH VJCOH OH OH OH COH 1130881 In certain embodiments of a compound of Formula (J) or (I), R 4 is selected from the group consisting of 35 18435 NH2 OH XOH OH NHrOH OH OH NH and 100891 In certain embodiments of a compound of Formula (J) or (I), R' s is selected from the group consisting of: s'Th OH cF3 NH2 \ „OH OH OH OH 0 LOH and 100901 In certain embodiments of a compound of Formula (J) or (I), le is selected from the group consisting of. 36 18435 Oy NH2 9OH OH CF3 OH 0 ....., 0 H ‘1/45..,11, rsil NHrOH OH 5\ \ 0 0 NH —5-0H ‘, ...li NH --r NH2 and 0 0 0 100911 In certain embodiments of a compound of Formula (J) or (I), 11 4 is selected from the group consisting of F3C9 '„0„ ICN;3 NH2 \ 0 0 \j ) OH ‘{i0 V\ OH NH OH OH 0 NH DOH and s ....ir NH --...-"-- NH2 0 0 0 (00921 In certain embodiments of a compound of Formula (J) or (I). R 4 is 37 18435 100931 In certain embodiments of a compound of Formula (J) or (1), R 4 is 100941 In certain embodiments of a compound of Formula (J) or (I), R ° is 100951 In certain embodiments of a compound of Formula (J) or (I), R 4 is 100961 In certain embodiments of a compound of Formula (I) or (I), le is 100971 In certain embodiments, the compound of Formula (I) or (I) is a compound of Formula (II) R3 Formula!! or a pharmaceutically acceptable salt thereof, wherein: It' is selected from the group consisting of hydrogen, halogen, and methyl; R6 is selected from the group consisting of hydrogen, halogen, and methyl; or R 5 6 together form an oxo group; and R R7 is selected from the group consisting of hydrogen, halogen, OR' and NR'R b; H? is selected from the group consisting of hydrogen and methyl; 38 18435 R9 is is selected from the group consisting of CiAalkyl, C34cycloalkyl, and —S- Ct-salkyl; Wand Rb are independently selected from the group consisting of hydrogen and C14alkyl; wherein each Cbsalkyl is optionally substituted with Ito 3 substituents independently selected from the group consisting of halogen, hydroxyl, and pyridyl; and R', le, and R 3 are as otherwise defined herein (00981 For example, in Formula (II), (Ha), and (lib), R' is selected from the group consisting of hydrogen, halogen, Cl.salkyl, CN, —S(0)1.21t1, and OR', wherein C14alkyl is optionally substituted with I to 5 R 2° groups; R2 is selected from the group consisting of hydrogen, halogen, C14alkyl, CN, —S(0)1.211" and OR', wherein C14alkyl is optionally substituted with I to 5 R 2° groups; and It' is selected from the group consisting of hydrogen, halogen, C14alkyl, CN, —NR°10, —S(0)1411*, and OR', wherein Cialkyl is optionally substituted with Ito 5 R 2° groups; 100991 In certain embodiments, the compound of Formula (II) is a compound of Formula (Ha) Nr NH2 R3 Formula Ha 101001 In certain embodiments, the compound of Formula (II) is a compound of Formula (J113) R3 Formula Jib. 101011 In certain embodiments of the compound of Formula (II), (Ha), or (fib), It 5 is hydrogen; R6 is hydrogen; or R' and R6 together form an oxo group; R 7 is OR' or NR'R''; 39 18435 I& is hydrogen; R9 is C1.4 alkyl, cyclopropyl or -SCH3; 12" and BY are independently selected from the group consisting of hydrogen and Cmalkyl; wherein each Cialkyl is optionally substituted with I to 3 substituents independently selected from halogen, hydroxyl, pyrid-2-yl, and CF3, and R I, R2, and fe are as otherwise defined herein. In certain embodiments, R' and BY are hydrogen. In certain embodiments, Ie is OH or NH2. In certain embodiments, R I and 1(2 are hydrogen. 101021 In certain embodiments of a compound of Formula (Ha), is selected from OH OH VC:3 NH2 OH and \4::CDH OH 101031 In certain embodiments of a compound of Formula (Ha), is selected from OH OH NH2 OH 0 40 18435 OH and 101041 In certain embodiments of a compound of formula (11b), ReiR9 R7 Ro gselRc5. is selected from " /2\ s' \ OH 0 Nj OH N(C:i OH NH OH o f3 , iNH...... 9"-OH and , i NHNH2 H -N 0 0 o 101051 In certain embodiments of a compound of formula (fib), is selected from \ s\,, d ,OH OH 0 H al OH N, NH OH 0 0 NH-...rNH2 0 41 18435 OH OH OH and 101063 In certain embodiments of the compound of Formula (II), (ha), or (I11), R 5 is hydrogen, R6 is hydrogen, or R5 and R6 together form an oxo group, R 7 is OR' or NWRb, 118 is hydrogen, le is CI-oalkyl, cyclopropyl or —SCH3, and Wand R b are independently selected from the group consisting of hydrogen and Cmalkyl, wherein each CI-salkyl is optionally substituted with I to 3 substituents independently selected from halogen, hydroxyl, pyrid-2-yl, and CF3. In certain embodiments of the compound of Formula (II), (Ha), or (lib), R7 is OH or NH2. 101071 In certain embodiments of a compound of Formula (J), Formula (I), or Formula (H), the compound is a compound of Formula (HI) HN RI N N A'NH2 R3 Formula (III) wherein R5 is hydrogen; le is hydrogen; or R5 and 116 together form an oxo group; R7 is selected from the group consisting of OR' and NR'R b; Wand It" are independently selected from the group consisting of hydrogen and C1.3alkyl; wherein each C1.3alkyl is optionally substituted with Ito 3 substituents independently selected from the group consisting of halogen and hydroxyl and IV, R2, and R3 are as otherwise defined herein. 101081 In certain embodiments the compound of Formula (111) is a compound of Formula (111a) 42 18435 112 HN Ra R- 1;1 R2 123 Formula (Ma) (01091 In certain embodiments the compound of Formula (III) is a compound of Formula (II1b) HN R1 N NH2 123 101101 In certain embodiments of the compound of Formula (III), (Ina), or (Mb), R 5 6 are both hydrogen and R7 is OR', wherein R' is hydrogen or CIAlkyl. In certain and R embodiments of the compound of Formula (III), (111a), or (Mb), 11 5 and R6 are both hydrogen and 127 is OH. In certain embodiments of the compound of Formula (III), (Ilia), or (Mb), R', 112,R5, and R6 are each hydrogen, and 117 is OH. 101111 In certain embodiments of the compound of Formula (III), (IIIa), or (Mb), R 5 6 together form an oxo group and R7 is selected from the group consisting of OR' and R and NR'Rb, wherein W and BY are independently selected from the group consisting of hydrogen and CI-Alkyl. In certain embodiments of the compound of Formula (III), (IIIa), or (Mb), R5 and R6 together form an oxo group and R 7 is selected from the group consisting of OR' and NWRb, wherein Wand RI' are independently selected from the group consisting of hydrogen and methyl. 101121 In certain embodiments of a compound of Formula (J), or Formula (1), the compound is a compound of Formula (IV): 43 18435 R3 Formula (IV) . 101131 The R', R2, and R3 groups of Formula (IV) are as defined above for Formula (J) or (I). The R", R' 2 and R'' groups are as defined above for 12 4 in Formula (J) or Formula (I). [0114] In certain embodiments, the compound of Formula (IV), or a pharmaceutically acceptable salt thereof, is a compound of Formula (IVa): Ri2 Ht4 fc NH2 R3 Formula (IVa) 101151 In certain embodiments, the compound of Formula (IV), or a pharmaceutically acceptable salt thereof, is a compound of Formula (IVb) . $11 ) R3 Formula (IVb). 101161 The groups RI, R2, R3, R", R" and R" of Formula (IVa) and (IVb) are as defined for Formula (J), (I) or (IV) above, or as defined below, or any combination thereof. 101171 IV of Formula (IV), (IVa) and (IVb) can be any suitable group selected from hydrogen, halogen, C14alkyl, CN, —S(0)1-2R', and OR', wherein CI-alkyl is 44 18435 optionally substituted with 1 to 5 R2° groups. In certain embodiments, R I is selected from hydrogen, halogen, C14 alkyl, CN, and OR', wherein C14 alkyl is optionally substituted with I to 5 R2° groups In certain embodiments, RI can be hydrogen, halogen, and C1.3 alkyl, wherein CI, alkyl is optionally substituted with 1 to 5 halogen groups. In certain embodiments, W can be hydrogen, fluoro, chloro, bromo, methyl or ethyl, wherein each methyl or ethyl group is optionally substituted with I to 5 halogen groups. In certain embodiments, RI can be hydrogen, fluor°, chloro, bromo, methyl or ethyl, wherein each methyl or ethyl group is optionally substituted with 1 to 5 fluoro groups. In certain embodiments, IV can be hydrogen, methyl, fluoro, chloro, and CF,. In certain embodiments, R I can be hydrogen In certain embodiments, IV is selected from hydrogen, halogen, N112, C14 alkyl, CN, and OW, wherein C14 alkyl is optionally substituted with 1 to 5 R2° groups. [0118J R2 of Formula (IV), (IVa) and (IVb) can be any suitable group selected from hydrogen, halogen, C14alkyl, CN, —NR112°, —S(0)1.2W and OR', wherein C14alkyl is optionally substituted with 1 to 5 R 2° groups. In certain embodiments, R2 is selected from hydrogen, halogen, C14 alkyl, CN, and OR', wherein C14 alkyl optionally substituted with 1 to 5 R2° groups. In certain embodiments, R 2 is selected from hydrogen, halogen, C1.3 alkyl, CN and OR', wherein C1-3 alkyl is optionally substituted with 1 to 5 halogen groups. In certain embodiments, R 2 is selected from hydrogen, methyl, ethyl, fluor°, chloro, bromo, CF3, CN, OH, OMe, and OEt. In certain embodiments, R2 is selected from hydrogen, methyl, fluoro, and chloro. In certain embodiments, R2 is selected from hydrogen and fluoro. In certain embodiments, R 2 is selected from hydrogen, halogen, N142, C14 alkyl, CN, and OR', wherein C14 alkyl is optionally substituted with I to 5 R2° groups. In certain embodiments, R2 is selected from hydrogen, methyl, ethyl, N142, fluoro, chloro, bromo, CF,, CN, OH, OMe, and OEt. 01191 R3 of Formula (IV), (IVa) and (IVb) can be any suitable group selected from hydrogen, halogen, Cialkyl, CN, —NWRb, —S(0)1.211', and OW, wherein Cialkyl is optionally substituted with I to 5 R 2° groups. In certain embodiments, R 3 is selected from hydrogen, halogen, C14 alkyl, CN, and OR', wherein C14 alkyl is optionally substituted with 1 to 5 R2° groups. In certain embodiments, R 3 can be selected from hydrogen, halogen, and C1.3 alkyl. In certain embodiments, R 3 can be selected from hydrogen, methyl, fluoro, and chloro. In certain embodiments, le can be selected from hydrogen and methyl. In certain embodiments, R 3 is selected from hydrogen, halogen, 45 18435 NH2, Ciz alkyl, CN, and Or, wherein C14 alkyl is optionally substituted with 1 to 5 R2° groups. [0120] In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein R I is selected from the group consisting of hydrogen, halogen, Ct.alkyl, CN, —NM I', —S(0)1.2W, and OR', wherein Cialkyl is optionally substituted with 1 to 5 R2° groups, R2 is selected from the group consisting of hydrogen, halogen, C14alkyl, CN, —NR•Rb, —S(0)1.2R• and OW, wherein Cialkyl is optionally substituted with 1 to 5 R20 groups, and R3 is selected from the group consisting of hydrogen, halogen, Cialkyl, CN, —NR'Rb, —S(0)1.211`, and OR', wherein Cialkyl is optionally substituted with 1 to 5 R2° groups. [0121] In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein R I is selected from the group consisting of hydrogen, halogen, and CI-3 alkyl, wherein C1.3 alkyl is optionally substituted with 1 to 5 halogen groups, R2 is selected from the group consisting of hydrogen, halogen, C1.3 alkyl, CN and OR', wherein C1.3 alkyl is optionally substituted with 1 to 5 halogen groups, and IV is selected from the group consisting of hydrogen, halogen, and CI.3 alkyl. 101221 In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein IV is selected from the group consisting of hydrogen, methyl, fluoro, chloro, and CF3, R 2 is selected from the group consisting of hydrogen, methyl, ethyl, fluoro, chloro, bromo, CF3, CN, OH, OMe, and OEt, and R3 is selected from the group consisting of hydrogen, methyl, fluoro, and chloro. [0123] In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein RI is selected from the group consisting of hydrogen, methyl, fluoro, chloro, and CF3, R 2 is selected from the group consisting of hydrogen, methyl, ethyl, NH2, fluoro, chloro, bromo, CF3, CN, OH, OMe, and OEt, and R3 is selected from the group consisting of hydrogen, methyl, fluoro, and chloro. [0124] In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein le is hydrogen, R 2 is 46 18435 selected from the group consisting of hydrogen, methyl, ethyl, fluoro, chloro, and bromo, and R3 is selected from the group consisting of hydrogen and methyl. [0125] In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein R I is hydrogen. R2 is selected from the group consisting of hydrogen and fluoro, and R 3 is selected from the group consisting of hydrogen and methyl. [0126] In certain embodiments, R" of Formula (IV), (IVa) and (IVb) can be any suitable group selected from hydrogen, C14 alkyl, C3.6 cycloalkyl, and CI-3 haloalkyl. In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein R" is selected from the group consisting of hydrogen, C1.2 alkyl and Ci..2 haloalkyl. In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein R" is selected from the group consisting of C1.2 alkyl and Ci.2 haloalkyl. In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein It" can be selected from hydrogen, methyl, ethyl or CF3. In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein RII can be selected from methyl, ethyl or CF3. In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein R II can be selected from hydrogen, methyl, or CF3. In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein It" can be selected from methyl, or CF3. In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein It" can be selected from hydrogen or methyl. In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, wherein It" is selected from the group consisting of methyl and CF3. In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein RII is methyl. In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein It" is hydrogen. 47 18435 101271 R12 of Formula (IV), (IVa) and (1Vb) can be any suitable group selected from C1.3 alkyl, halogen, -OR', —NWRb, CN, —C(0)W, —C(0)0W, —C(0)NWItb, — 0C(0)NRIRb, —4WC(0)Rb, —NleC(0)NRb,—NWC(0)0Rb, —SR', —S(0)1.2W, — S(0)2NR'llb, —NR2S(0)2Rb, C1-3 haloalkyl, C3_6 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, C6.loaryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered hetcroaryl has Ito 3 hetcroatoms selected from oxygen, nitrogen, and sulfur, wherein the C1-3 alkyl group is optionally substituted with 1 to 5 substituents independently selected from halogen, -OR', —NM I', CN, —C(0)W, —C(0)011*, — C(0)NR'Rb, —0C(0)NR'Rb, —NWC(0)1e, —NR*C(0)NR1), —NRIC(0)0Rb, —SR', —S(0),. 2R', —S(0)2NR'Rb, —NWS(0)2Rb, CI-3 haloalkyl, C34 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, C6.maryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has Ito 3 heteroatoms selected from oxygen, nitrogen, and sulfur. [01281 In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, wherein W 2 can be selected from C1.2 alkyl, — C(0)NR'Rb, and 5 membered heteroaryl having 1 to 3 nitrogen heteroatoms, wherein Cl. 2 alkyl is optionally substituted with 1 to 5 substituents independently selected from halogen, -OH, —NIVEL'', —NWC(0)R b, —NWS(0)2Rb, and CI., haloalkyl, and each Wand Rb is independently selected from the group consisting of hydrogen and CI., alkyl, wherein each C1.3 alkyl is optionally substituted with 1 to 3 substituents independently selected from hydroxyl and amino. In certain embodiments, the compound of Formula (IV), (IVa) or (nib), or a pharmaceutically acceptable salt thereof, wherein 11 12 is CI-2 alkyl, optionally substituted with I to 3 substituents independently selected from halogen, -OH, —NJ-h, —N1-1C(0)-C13 alkyl, —NIIS(0)2-CI.3 alkyl, and CI-3 haloalkyl. In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, wherein R 12 is methyl or ethyl, each optionally substituted with 1 or 2 substituents independently selected from halogen, -OH, —NH2, — NFIC(0)-C1.3 alkyl, and C1.3 haloalkyl. In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, wherein R 12 is methyl or ethyl, wherein the methyl or ethyl is substituted with 1 or 2 substituents independently selected from —OH and -NHC(0)CH3. In certain embodiments, the 48 18435 compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, wherein R12 can be selected from CH2OH, CH2C1120H, CII(Me)OH, CH(CH2F)OH, CH(CHF2)0H, CH(CF3)0H, CF3, CH224/12, CH2NHC(0)Me, CII(CH2F)NIIC(0)Me, CH2NHS(0)2Me, C(0)NH2, C(0)NHMe, C(0)N11-012CH2011, C(0)NH-CH2CH2NH2, C(0)NH-(pyridin-2-ylmethyl), imidazolyl, and triazolyl. In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, wherein R' 2 can be selected from CH2OH, CH(Me)OH, C1(C112F)OH, and CH2NHC(0)Me. In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, wherein V can be selected from CH2OH, CH(Me)OH, and CH2NHC(0)Me. In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, wherein I1 12 is -CH2OH or -CH2NC(0)CH3. 101291 In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, wherein R 12 is C1.2 alkyl substituted with - NRIC(0)Rb, wherein each Wand 111) is independently selected from the group consisting of hydrogen and C1.3 alkyl, wherein each CI-3 alkyl is optionally substituted with 1 to 3 substituents independently selected from hydroxyl and amino. 101301 Au of Formula (IV), (IVa) and (IVb) can be any suitable group selected from C14 alkyl, halogen, -OR', -NR'Rb, CN, -C(0)11", -C(0)011 1, -C(0)NR'Rb, - 0C(0)NR1Rb, -NWC(0)Rb, -Nlit(0)NRb, -4RIC(0)0Rb, -SR', -S(0)1.211', - S(0)2NR'Rb, -NR'S(0)2Rb, C1.6 haloalkyl, C34 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has I to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, C6.10aryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, wherein the C14 alkyl is optionally substituted with 1 to 5 substituents independently selected from halogen, -OR', -NR'Rb, CN, -C(0)11', -C(0)011', - C(0)NR'Rb, -0C(0)NWIth, -NR'C(0)R", -NIVC(0)NRb, -NItt(0)0Rb, -SR', -5(0)1. 2R', -S(0)2NR1Rb, -4R'S(0)2Rb, C1.6 haloalkyl, C34 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, C6-10 aryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has Ito 3 heteroatoms selected from oxygen, nitrogen, and sulfur. 49 18435 [01311 In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein R" is C34 alkyl optionally substituted with 1 to 2 substituents independently selected from halogen and - OH. In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein R' 3 is C3_6 alkyl optionally substituted with 1 to 2 halogen substituents. In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein R' 3 is C3-6 alkyl. Representative C34 alkyl groups for R' 3 include, but are not limited to, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert- butyl, n-pentyl, tert-pentyl, neopentyl, isopentyl, sec-pentyl and 3-pentyl. In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein Ru is propyl, butyl or pentyl. In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein R' 3 is n-propyl, n- butyl or n-pentyl. In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein R D is propyl or butyl. 101321 Rw of Formula (IV), (IVa) and (IVb) can be any suitable group selected from halogen, Ci4haloalkyl, CN, S(0)1.2121, and OR'. In certain embodiments, each R2° can independently be selected from halogen, CN, —NR 110, and OR'. In certain embodiments, each 1120 can independently be selected from halogen, CN, —NR'Rb, and OR'. In certain embodiments, each R 2° can independently be halogen. In certain embodiments, each R2° can independently be selected from fluoro, chloro, bromo, CN, — NH2, OH, OMe, and OEt. In certain embodiments, each R 2° can independently be selected from fluoro and chloro. 101331 R' and Rb of Formula (IV), (IVa) and (IVb) can each independently be any suitable group selected from the group consisting of hydrogen and Cl4alkyl; wherein each Ci4alkyl is optionally substituted with 1 to 5 substituents independently selected from halogen, hydroxyl, amino, 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, and CI4haloalkyl. In certain embodiments, R' and R b can each independently be selected from hydrogen and C1-3 alkyl, wherein each CI-3 alkyl is optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxyl, amino, and C14 50 18435 haloalkyl. In certain embodiments, Ft' and Rh can each independently be selected from hydrogen and C1-3 alkyl, wherein each C1.3 alkyl is optionally substituted with 1 to 3 substituents independently selected from hydroxyl and amino. In certain embodiments, R.' and Rh can each independently be selected from hydrogen and C1.3 alkyl, wherein each C1.3 alkyl is optionally substituted with 1 substituent selected from hydroxyl and amino. In certain embodiments, R' and Rh can each independently be selected from hydrogen and C1.3 alkyl. In certain embodiments, R' and Rh can each independently be selected from hydrogen, methyl, ethyl, propyl, butyl, CF3, CH2CF3, CH2CH2CF3, CH2OH, CH2CH2OH, CH2NH2, and CH2CH2NH2. In certain embodiments, R' and R h can each independently be selected from hydrogen, methyl, ethyl, CF,, CH2OH, CH2CH2OH, CH2NH2, and CH2CH2NH2. In certain embodiments, R' and R h can each independently be selected from hydrogen, methyl, ethyl, CH2CH2OH, and CH2012NH2. In certain embodiments, R' and Rh can each independently be selected from hydrogen, methyl and ethyl. In certain embodiments, R' and R h can each independently be selected from hydrogen and methyl. 101341 In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein: R' is selected from the group consisting of hydrogen, halogen, Cialkyl, CN, — NR'Rh, —S(0)1.211', and OR', wherein C1.6alkyl is optionally substituted with 1 to 5 le° groups; R2 is selected from the group consisting of hydrogen, halogen, Cialkyl, CN, NRIRb —S(0)1.2111 and OR', wherein Cialkyl is optionally substituted with 1 to 5 R2° groups; R' is selected from the group consisting of hydrogen, halogen, Cialkyl, CN, NRIRb —S(0)1.2r, and OR', wherein CI-alkyl is optionally substituted with 1 to 5 R2° groups; R11 is selected from the group consisting of hydrogen, C1.2 alkyl, C3.6 cycloalkyl, and C1-3 haloalkyl; Rn is selected from Ci.3 alkyl, halogen, -OR', CN, —C(0)111, —C(0)0111, —C(0)NR'Ith, —0C(0)NR'Rh, .44IVC(0)10, —NR.C(0)NIth, — NWC(0)0Rh, —SR', —S(0)[.211", —S(0)2NWRY, —NR*S(0)21th, haloalkyl, C34 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has I to 3 heteroatoms selected from oxygen, 51 18435 nitrogen, and sulfur, Cs_m aryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, wherein the C1.3 alkyl group is optionally substituted with 1 to 5 substituents independently selected from halogen, - OR', —NRIRb, CN, —C(0)11', —C(0)0121, —C(0)NR'Rb, —0C(0)NRIRb, — NRIC(0)Rb, —NRIC(0)NRb, —NRIC(0)0Rb, —SR', —S(0)1.211', — S(0)2NR9e, —NR'S(0)2Rb, C1.3 haloalkyl, C3-6 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, C6-10 aryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur; R" is selected from C14 alkyl, halogen, -OR', —NRIR b, CN, —C(0)111, —C(0)011", —C(0)N1VR1', —0C(0)NRIRb, —Nlit(0)Rb, —NRIC(0)NRb, — NRIC(0)0Rb, —SR', —S(0)1.211,, —S(0)2NR'Rb, —NR'S(0)2Rb, C1-6 haloalkyl, C3-6 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, C6.waryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, wherein the C1-6 alkyl is optionally substituted with 1 to 5 substituents independently selected from halogen, - OR', —NRIRb, CN, —C(0)1V, —C(0)0R2, —C(0)NR'Rb, —0C(0)NRIRb, — NRIC(0)Rb, —NR,C(0)NRb, —NR*C(0)0Rb, —SR', —S(0)1.2R*, — S(0)2NR1Rb, —NR'S(0)2Rb, Ci4 haloalkyl, C34 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, C6-10 aryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur; each R2° is independently selected from the group consisting of halogen, CN, — NRIRb, and OR'; and each and Rb is independently selected from the group consisting of hydrogen and C1-3 alkyl, wherein each C1-5 alkyl is optionally substituted with Ito 3 52 18435 substituents independently selected from halogen, hydroxyl, amino, and CI-6 haloalkyl. 101351 In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein: 111 is selected from the group consisting of hydrogen, halogen, Cialkyl, CN, — NR'Rb, —S(0)1.21V, and OR', wherein CI-alkyl is optionally substituted with 1 to 5 R2° groups; R2 is selected from the group consisting of hydrogen, halogen, CI-alkyl, CN, — NR'Rb, —S(0)1.212' and OR', wherein CI-alkyl is optionally substituted with 1 to 5 R2° groups; K3 is selected from the group consisting of hydrogen, halogen, Cksalkyl, CN, —S(0)1.21e, and OR', wherein Ctalkyl is optionally substituted with 1 to 5 R2° groups; 1111 is selected from the group consisting of C1.2 alkyl, C3.4 cycloallcyl, and CI-3 haloalkyl; Rn is selected from C1.3 alkyl, halogen, -OR', —NRIR b, CN, —C(0)R', —C(0)0r, —C(0)NR*Rb, —0C(0)NRIRb, —NWC(0)Rb, —NR*C(0)NRb, — NWC(0)0Rb, —SR', —S(0)t-2R', —S(0)2NR'Rb, —NR'S(0)2Rb, haloalkyl, C34 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, C6.10aryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, wherein the C1-3 alkyl group is optionally substituted with 1 to 5 substituents independently selected from halogen, - OR', CN, —C(0)R1, —C(0)0r, —C(0)NR'Rb, —0C(0)NR'Rb, — NWC(0)Rb, —NR1C(0)NRb, —NR1C(0)0Rb, —SR', —S(0)1.21r, — S(0)2NR'Rb, —NR'S(0)2Rb, C1.3 haloalkyl, C34 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, C6-maryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur; 53 18435 R' 3 is selected from C1.6 alkyl, halogen, -OR', —NR'R b, CN, —C(0)Its, —C(0)01111, —C(0)NR'Rb, —0C(0)NR'Rb, —NRIC(0)Rb, —NRIC(0)Nltb, — NR*C(0)0Rb, —SR', —S(0)1.211', —S(0)2NR112.1', —NR'S(0)2Rb, C1-6 haloalkyl, C34 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, Cs.loaryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, wherein the C14 alkyl is optionally substituted with 1 to 5 substituents independently selected from halogen, - OR', CN, —C(0)111, —C(0)012.1, —C(0)NR'llb, —0C(0)NR'Rb, — NRIC(0)Rb, —NRIC(0)NRb, —NRIC(0)0Rb, —SR', —S(0)1.211', — S(0)2NR°11b, —NR'S(0)2Rb, C1.6 haloalkyl, C3-6 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, C6-loaryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has I to 3 heteroatoms selected from oxygen, nitrogen, and sulfur; each R2° is independently selected from the group consisting of halogen, CN, — NR'Rb, and OR'; and each W and Ft" is independently selected from the group consisting of hydrogen and C1-3 alkyl, wherein each C1-3 alkyl is optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxyl, amino, and C14 haloalkyl. 101361 In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein: RI is selected from the group consisting of hydrogen, halogen, CI.6 alkyl, CN, and OR', wherein C14 alkyl is optionally substituted with I to 5 R2° groups; R2 is selected from the group consisting of hydrogen, halogen, C14 alkyl, CN, and OR', wherein C1.6 alkyl optionally substituted with 1 to 5 R 2° groups; 113 is selected from the group consisting of hydrogen, halogen, C145 alkyl, CN, and OR', wherein C14 alkyl is optionally substituted with Ito 5 R 2° groups; 54 18435 R" is selected from the group consisting of hydrogen, C1.2 alkyl, C3-6 cycloalkyl, and C1.3 haloalkyl; R12 is selected from C1.3 alkyl, halogen, -OR', -NRIR b, CN, -C(0)11", -C(0)01V, -C(0)NRIRb, -0C(0)NRIRb, -NRIC(0)Rb, -NRIC(0)NRb, - NRIC(0)0Rb, -SR', -S(0)1.2R', -S(0)2NR'R b, -NR*S(0)2Rb, haloalkyl, C3-6 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, C6_10aryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has Ito 3 heteroatoms selected from oxygen, nitrogen, and sulfur, wherein the C1.3 alkyl group is optionally substituted with 1 to 5 substituents independently selected from halogen, - OR', -NRIRb, CN, -C(0)1V, -C(0)011*, -C(0)NRIlt b, -0C(0)NRIRb, - NWC(0)Rb, -NRIC(0)NRb, -NRIC(0)0Rb, -SR', -S(0)1.21V, - S(0)2NR'Rb, -NWS(0)2Rb, C1.3 haloalkyl, C3.6 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, C6.loaryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur; R" is selected from C14 alkyl, halogen, -OR', CN, -C(0)1V, -C(0)0W, -C(0)NRIRb, -0C(0)NR'Rb, -NRIC(0)Rb, -NRIC(0)NRb, - NRIC(0)0Rb, -SR', -S(0)1.2111, -S(0)2NR'Rb, -NRIS(0)2Rb, Ct-6 haloalkyl, C3_6 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, C6.maryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has Ito 3 heteroatoms selected from oxygen, nitrogen, and sulfur, wherein the C14 alkyl is optionally substituted with 1 to 5 substituents independently selected from halogen, - OR', -NRIRb, CN, -C(0)RI, -C(0)0r, -C(0)NRIR b, -0C(0)NRIRb, - NRIC(0)Rb, -NRIC(0)NRb, -NRIC(0)0Rb, -SR', -S(0)1.21V, - S(0)2NR'Rb, 44R'S(0)2Rb, C1-6 haloalkyl, C34 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has I to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, C6-10 aryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered 55 18435 heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur; each R2° is independently selected from the group consisting of halogen, CN, — NR*11b, and OR'; and each R' and Rb is independently selected from the group consisting of hydrogen and C1.3 alkyl, wherein each C1.3 alkyl is optionally substituted with Ito 3 substituents independently selected from halogen, hydroxyl, amino, and C14 haloalkyl. 101371 In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is the compound wherein: RI is selected from the group consisting of hydrogen, halogen, C14 alkyl, CN, and OR', wherein C14 alkyl is optionally substituted with 1 to 5 R 2° groups; 122 is selected from the group consisting of hydrogen, halogen, C1.6 alkyl, CN, and OW, wherein C14 alkyl optionally substituted with 1 to 5 R 2° groups; R3 is selected from the group consisting of hydrogen, halogen, C14 alkyl, CN, and OR', wherein C1.6 alkyl is optionally substituted with 1 to 5 R2° groups; R" is selected from the group consisting of Ct.2 alkyl, C34 cycloalkyl, and C1-3 haloalkyl; R12 is selected from C1.3 alkyl, halogen, -OR', —NR'Rb, CN, —C(0)111, —C(0)01V, —C(0)NR'Rb, —0C(0)NR'Rb, —NRIC(0)111', —NIVC(0)Ne. — NRIC(0)0Rb, —SR', —S(0)1-2111, —S(0)2NR'Rb, —NR'S(0)2Rb, C1.3 haloalkyl, C34 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, C6.10 aryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has Ito 3 heteroatoms selected from oxygen, nitrogen, and sulfur, wherein the C1.3 alkyl group is optionally substituted with 1 to 5 substituents independently selected from halogen, - OR', —NR'Rb, CN, —C(0)W, —C(0)011', —C(0)NR'R b, —0C(0)NR'Rb, — NRIC(0)Rb, —NRIC(0)NRb, —NRIC(0)0Rb, —SR', —S(0)1.211', — S(0)2NIVRb, —NWS(0)2Rb, CI-3 haloalkyl, C34 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 56 18435 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, C6.10 aryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur; R13 is selected from C1.6 alkyl, halogen, -OR', —NR'Rb, CN, —C(0)W, —C(0)OR', —C(0)NR*Rb, —0C(0)NR'llb, —NR'C(0)Rb, —NWC(0)NRb, — NWC(0)0Rb, —SR', —S(0)1.212", —S(0)2NWW, —NR'S(0)2Rb, Ct.6 haloalkyl, C3-6 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, Cs_loaryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, wherein the C1.6 alkyl is optionally substituted with 1 to 5 substituents independently selected from halogen, - OR', —NR'Rb, CN, —C(0)W, —C(0)012', —C(0)NR'le, —0C(0)NR'Rb, — NWC(0)Rb, —NWC(0)NRb, —NWC(0)0114, —SR', —S(0)1.2W, — S(0)2NR1Rb, —NR'S(0)2Rb, CI4 haloalkyl, C34 cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, C5.10 aryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur; each R2° is independently selected from the group consisting of halogen, CN, — NR'Rb, and OR'; and each Wand Rb is independently selected from the group consisting of hydrogen and C13 alkyl, wherein each C1.3 alkyl is optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxyl, amino, and C14 haloalkyl. [0138] In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, wherein R" is methyl or CF3, R 12 is -CH2OH, - CH(Me)OH or -CH2NHC(0)CH3, and R 13 is selected from the group consisting of propyl, butyl and pentyl. 101391 In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, wherein R" is methyl or CF3, R 12 is -CH2OH, - 57 18435 CH(Me)OH, CH2NHCH(CI13)(CF3) or -CH2NHC(0)CH3, and It" is selected from the group consisting of propyl, butyl and pentyl. 101401 In certain embodiments, the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt thereof, wherein R" is methyl, R" is -CH2OH or - CH2NHC(0)CH3, and It" is selected from the group consisting of propyl and butyl. 101411 In certain embodiments, the compound of Formula (IV), or a pharmaceutically acceptable salt thereof, wherein the moiety is \\ <,,OH <.,OH 1,0H C,FCliFi CIDFi r()H <1,0F1 C,OH 101421 In certain embodiments, the compound of Formula (IV), or a pharmaceutically acceptable salt thereof, wherein the moiety is 58 18435 CF3 2,0H 0H .gC.OH 0H N, 1,0H <,OH S., 0 0 or (01431 In certain embodiments, the compound of Formula (IV) or (IVa), or a pharmaceutically acceptable salt thereof, wherein the moiety is OH S., 11%0 0 , or [01441 In certain embodiments, the compound of Formula (IV) or (IVa), or a pharmaceutically acceptable salt thereof, wherein the moiety Ri3 Rii \e1112 is 59 18435 OH S ., 11%0 0 , or 101451 In certain embodiments, the compound of Formula (IV) or (IVa), or a pharmaceutically acceptable salt thereof, wherein the moiety Ne: R12 rifF3 is CH3 or 101461 In certain embodiments, the compound of Formula (IV) or (IVa), or a pharmaceutically acceptable salt thereof, wherein the moiety R13 R11 R12 is 101471 In certain embodiments, the compound of Formula (IV) or (IVa), or a pharmaceutically acceptable salt thereof, wherein the moiety 60 18435 can also be drawn as the moiety [0148] In certain embodiments, the compound of Formula (IV) or (IVb), or a pharmaceutically acceptable salt thereof, wherein the moiety R13 B11 12 NVR is Or 101491 In certain embodiments, the compound of Formula (IV) or (IVb), or a pharmaceutically acceptable salt thereof, wherein the moiety R13 Bi I 12 N61 can also be drawn as the moiety R" fi" 101501 In certain embodiments, the compound of Formula (IV) or (IVa), or a pharmaceutically acceptable salt thereof, is a compound of Formula (IVc) Formula (IVc) . 101511 The R2, R12 and Ru groups of Formula (IVc) are as defined above for Formula (J), (I), (IV) or (IVa), or any combination thereof. For example, R 2 can be selected from hydrogen, halogen. C1.3 alkyl, CN and OR', wherein Ci.3 alkyl is optionally substituted with 1 to 5 halogen groups, R 12 can be selected from C1.2 alkyl, —C(0)NRIR b, and 5 61 18435 membered heteroaryl having I to 3 nitrogen heteroatoms, wherein CI.2 alkyl is optionally substituted with I to 5 substituents independently selected from halogen, -OH, —NR'R b, — NWC(0)Rb, —NR'S(0)2Rb, and C1-3 haloalkyl, and R' 3 can be C3.6 alkyl optionally substituted with I to 2 substituents independently selected from halogen and -OH. In certain embodiments, the compound of Formula (IV), (IVa), or (IVc), or a pharmaceutically acceptable salt thereof, is a compound wherein R 2 can be selected from hydrogen, methyl, ethyl, fluoro, chloro, bromo, CF3, CN, OH, OMe, and OEt, and R' 2 can be selected CH2OH, CH2CH2OH, CH(Me)OH, CH(CH2F)OH, CH(CHF2)0H, CH(CF3)0H, CF3, CH2NH2, CH2MIC(0)Me, CH(CH2F)NHC(0)Me, CH2NHS(0)2Me, C(0)NH2, C(0)NHMe, C(0)NH-CF12CH2OH, C(0)NH-CH2CH2NH2, C(0)NH- (pyridin-2-ylmethyl), imidazolyl, and triazolyl, and R' 3 can be propyl, butyl or pentyl. In certain embodiments, the compound of Formula (IV), (IVa), or (IVc), or a pharmaceutically acceptable salt thereof, is a compound wherein R 2 can be selected from hydrogen, methyl, fluoro, and chloro, and R' 2 can be selected C1420H, CH(Me)OH, CH(CH2F)OH, and CH2NHC(0)Me, and R' 3 can be propyl, butyl or pentyl. In certain embodiments, the compound of Formula (IV), (IVa), or (IVc), or a pharmaceutically acceptable salt thereof, is a compound wherein R2 is hydrogen or fluoro, Ru is -CH2OH or -CH2NHC(0)CH3, and R" is selected from propyl and butyl. In certain embodiments, the compound of Formula (IV), (IVa), or (IVc), or a pharmaceutically acceptable salt thereof, is a compound wherein R2 is hydrogen, chloro, or fluor°, R' 2 is -CH2OH or - CH2NHC(0)CH3, and R" is selected from butyl or pentyl. (01521 In certain embodiments, the compound of Formula (IV) or (IVa), or a pharmaceutically acceptable salt thereof, is a compound of Formula (IVd) R3 Formula (IVd) . 101531 The R', R2, le, R'', R", R' and Rb groups of Formula (IVd) can be as defined above for Formula (J), (0, (IV), or (IVa), or any combination thereof R 12' can be any suitable group selected from hydrogen, C14 alkyl and C1.3 haloalkyl. In certain embodiments, the compound of Formula (IV), (IVa) or (IVd), or a pharmaceutically 62 18435 acceptable salt thereof, is a compound wherein IV' can be selected from hydrogen, C1.2 alkyl and C1.3 haloalkyl. In certain embodiments, the compound of Formula (IV), (IVa) or (IVd), or a pharmaceutically acceptable salt thereof, is a compound wherein 11 12' can be selected from hydrogen, methyl, ethyl and CF3. In certain embodiments, the compound of Formula (IV), (IVa) or (lVd), or a pharmaceutically acceptable salt thereof, is a compound wherein 11 12' can be hydrogen. 101541 In certain embodiments, the compound of Formula (IVd), or a pharmaceutically acceptable salt thereof, is the compound wherein RI is selected from the group consisting of hydrogen, halogen, C14 alkyl, CN, and OR', wherein C14 alkyl is optionally substituted with Ito 5 R2° groups, R2 is selected from the group consisting of hydrogen, halogen, C14 alkyl, CN, and OR', wherein C14 alkyl optionally substituted with 1 to 5 R2° groups, R3 is selected from the group consisting of hydrogen, halogen, C1.6 alkyl, CN, and OR', wherein C14 alkyl is optionally substituted with Ito 5 R 2° groups, R" is C1-2 alkyl or CF3, R"' is selected from the group consisting of hydrogen, C1.2 alkyl and C1.3 haloalkyl, 12" is C34 alkyl optionally substituted with I to 2 halogen substituents, each R2° is independently selected from the group consisting of halogen, C14haloalkyl, CN, —NIVItb, S(0)1.211*, and OR', and each Its and le is independently selected from the group consisting of hydrogen and C1.3 alkyl, wherein each C1.3 alkyl is optionally substituted with I to 3 substituents independently selected from halogen, hydroxyl, amino, and C14 haloallcyl. 101551 In certain embodiments, the compound of Formula (IVd), or a pharmaceutically acceptable salt thereof, is the compound wherein R I is selected from the group consisting of hydrogen, halogen, and C1.3 alkyl, R2 is selected from the group consisting of hydrogen, halogen, and C1.3 alkyl, R3 is selected from the group consisting of hydrogen, halogen, and CI.3 alkyl, R" is C1.2 alkyl or CF3,1112' is selected from the group consisting of hydrogen, C14 alkyl and C1.3 haloalkyl, R" is C34 alkyl optionally substituted with Ito 2 halogen substituents, and each rand It" is independently selected from the group consisting of hydrogen and C1-3 alkyl, wherein each C1.3 alkyl is optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxyl, amino, and C14 haloalkyl. 101561 In certain embodiments, the compound of Formula (IVd), or a pharmaceutically acceptable salt thereof, has the structure: 63 18435 3 HN' R123 0 N R2 N NH2 R3 wherein R2 is selected from the group consisting of hydrogen, methyl, fluoro, and chloro, R3 is selected from the group consisting of hydrogen and methyl, 12 12° is selected from the group consisting of hydrogen, C1.2 alkyl and C14 haloalkyl, 11 13 is C34 alkyl, and Rb is methyl or ethyl, each optionally substituted with hydroxyl or amino. 101571 In certain embodiments, the compound of Formula (IVd), or a pharmaceutically acceptable salt thereof, has the structure: 3 N Rb HN' R'2' N R2 N#L NH2 wherein R2 is selected from the group consisting of hydrogen, methyl, fluoro, and chloro, R12a is selected from the group consisting of hydrogen, C1-2 alkyl and C1.3 haloalkyl, 1113 C34 alkyl, and Rb is methyl or ethyl, each optionally substituted with hydroxyl or is amino. In certain embodiments, R2 and R13 can be as defined above for Formula (J), (I), (IV), or (IVa), or any combination thereof 101581 In certain embodiments, the compound of Formula (IVd), or a pharmaceutically acceptable salt thereof, has the structure: R3 wherein R3 is selected from the group consisting of hydrogen and methyl, 12.' 2 is selected from the group consisting of hydrogen, C14 alkyl and CI-3 haloalkyl, Ru is C34 alkyl, and is methyl or ethyl, each optionally substituted with hydroxyl or amino. 101591 In certain embodiments, the compound of Formula (IVd), or a pharmaceutically acceptable salt thereof, has the structure: 64 18435 131t11 Kg' y RI N 0 *L R2 NH2 R3 wherein R" is C34 alkyl. IV, R2 and R3 can be as defined above for Formula (J), (I), (IV), (IVa) or (IVd). 101601 In certain embodiments, the compound of Formula (IVd), or a pharmaceutically acceptable salt thereof, has the structure: RtU H 0 R2 N#LNH2 wherein R2 is selected from the group consisting of hydrogen and F, and R" is C3.6 alkyl. In certain embodiments, R2 and R13 can be as defined above for Formula (J), (I), (IV), or (IVa), or any combination thereof. 101611 In certain embodiments, the compound of Formula (IVd), or a pharmaceutically acceptable salt thereof, has the structure: R2 NH2 wherein R2 is selected from the group consisting of hydrogen, Cl,. and F, and R" is C34 alkyl. In certain embodiments, R2 and R" can be as defined above for Formula (.1), (I), (IV), or (IVa), or any combination thereof. 101621 In certain embodiments, the compound of Formula (IVd), or a pharmaceutically acceptable salt thereof, has the structure: Riq HN`e 0 *LNH2 R3 65 18435 wherein re is selected from the group consisting of hydrogen and methyl, and II" is C3_6 alkyl. [0163] In certain embodiments, the compound of Formula (J), (I), or (IV), is selected from: and or a pharmaceutically acceptable salt thereof. [0164] In certain embodiments, the compound of Formula (J), (I), or (IV), is selected from: cil 66 18435 CI and or a pharmaceutically acceptable salt thereof. 101651 In certain embodiments, the compound of Formula (.1), (I), or (IV), or a pharmaceutically acceptable salt thereof, is a compound of the following formula: N,R b R12' o N N#L NH2 R3 wherein RI is selected from the group consisting of hydrogen, halogen, CI4 alkyl, CN, and OR', wherein CIA alkyl is optionally substituted with I to 5 R20 groups, R2 is selected from the group consisting of hydrogen, halogen, C14 alkyl, CN, and OR', wherein C14 alkyl optionally substituted with Ito 5 R 2° groups, R3 is selected from the group consisting of hydrogen, halogen, CIA alkyl, CN, and OR', wherein CI4 alkyl is optionally substituted with I to 5 R2° groups, RI2' is selected from the group consisting of hydrogen, C1.2 alkyl and C1.3 haloalkyl, RI 3 is C345 alkyl optionally substituted with I to 2 halogen substituents, each R2° is independently selected from the group consisting of halogen, Ci.shaloalkyl, CN, —NR'R b, S(0)1.211', and OR', and each RI and R b is independently selected from the group consisting of hydrogen and alkyl, wherein each C1.3 alkyl is optionally substituted with I to 3 substituents independently selected from halogen, hydroxyl, amino, and C14 haloalkyl. 101661 In certain embodiments, the compound of Formula (I), (I), or (IV), or a pharmaceutically acceptable salt thereof, is a compound of the following formula: 67 18435 R3 wherein RI is selected from the group consisting of hydrogen, halogen, and C1.3 alkyl, R 2 3 is selected is selected from the group consisting of hydrogen, halogen, and C1.3 alkyl, R from the group consisting of hydrogen, halogen, and C1.3 alkyl, R 12a is selected from the group consisting of hydrogen, C1-2 alkyl and C1.3 haloalkyl, R" is C3.6 alkyl optionally substituted with Ito 2 halogen substituents, and each R' and R b is independently selected from the group consisting of hydrogen and C1.3 alkyl, wherein each C1.3 alkyl is optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxyl, amino, and Cizhaloalkyl. [0167] In certain embodiments, the compound of Formula (J), (I), or (IV), or a pharmaceutically acceptable salt thereof, is a compound of the following formula: RI N 0 R2 R3 wherein R" is C3.6 alkyl. R I, R2 and le can be as defined above for Formula (J), (I), (IV), (IVa) or (IVd). 101681 In certain embodiments of a compound of Formula (J), (I), (II), (Ha), (fib), (III), (IIIa), or (11th), R I is hydrogen, halogen, or C1.6alkyl optionally substituted with I to 5 R2° groups. In certain embodiments of a compound of Formula (J), (I), (II), (Ha), (I1b), (III), (Ma), (IIIb), (IV), (IVa), (IVb), or (IVd), RI is hydrogen, halogen, or Ci. 6alkyl optionally substituted with 1 to 5 R2° groups. [0169] In certain embodiments of a compound of Formula (J), (I), (II), (lb), (IIb), (III), (11Ia), or (IIIb), RI is hydrogen, halogen, or C1.3alkyl optionally substituted with 1 to 5 halogens. In certain embodiments of a compound of Formula (J), (I), (II), (Ha), (11b), (III), (Ma), (11th), (IV), (IVa), (IVb) or (IVd), IV is hydrogen, halogen, or Ciaalkyl optionally substituted with 1 to 5 halogens. 68 18435 101701 In certain embodiments of a compound of Formula (J), (I), (II), (Ha), (lib), (III), (Lila), or (Mb), RI is hydrogen, Cl, CH3, or CF3. In certain embodiments of a compound of Formula (J), (I), (II), (ha), (lib), (III), (IIIa), (111b), (IV), (IVa), (IVb) or (IVd), RI is hydrogen, Cl, CH3, or CF3. 101711 In certain embodiments of a compound of Formula (1), (I), (II), (ha), (I1b), (III), (Ma), or (IIIb), R2 is hydrogen, halogen, CN, or ClAsalkyl optionally substituted with Ito 5 R2° groups. In certain embodiments of a compound of Formula (J), (I), (II), (ha), (11b), (III), (Ilia), (IIIb), (IV), (IVa), (IVb), (IVc), or (IVd), R 2 is hydrogen, halogen, CN, or C14alkyl optionally substituted with 1 to 5 R 2° groups. 101721 In certain embodiments of a compound of Formula (J), (I), (II), (Ha), (Jib), (III), (IIIa), or (Mb), R2 is hydrogen, halogen, CN or C1.3alkyl optionally substituted with Ito 5 halogens. In certain embodiments of a compound of Formula (J), (I), (II), (ha), (Jib), (III), (IIIa), (111b), (IV), (IVa), (IVb), (IVc), or (IVd), R 2 is hydrogen, halogen, CN or C1.3alkyl optionally substituted with 1 to 5 halogens. 101731 In certain embodiments of a compound of Formula (J), (I), (II), (ha), (Jib), (III), (11Ia), or (Mb), R2 is hydrogen, CH3, -Ch2CH3, F, Br, Cl, or CN. In certain embodiments of a compound of Formula (J), (I), (II), (Ha), (11b), (III), (111a), (Bib), (IV), (IVa), (IVb), (IVc), or (IVd), R 2 is hydrogen, CH3, -CH2CH3, F, Br, Cl, or CN. 101741 In certain embodiments of a compound of Formula (1), (I), (II), (ha), (11b), (III), (IIIa), or (Mb), R3 is hydrogen, halogen, or CIAalkyl optionally substituted with I to 5 R20 groups. In certain embodiments of a compound of Formula (J), (I), (II), (11a), (I1b), (III), (Ina), (Mb), (IV), (IVa), (IVb) or (IVd), R 3 is hydrogen, halogen, or Cpsalkyl optionally substituted with I to 5 R2° groups. 101751 In certain embodiments of a compound of Formula (J), (1), (II), (1Ia), (Ilb), (III), (11Ia), or (111b), R3 is hydrogen, halogen, or C1.3alkyl optionally substituted with I to 5 R2° groups. In certain embodiments of a compound of Formula (J), (I), (II), (Ha), (IIb), (III), (Ina), (Mb), (IV), (IVa), (IVb) or (IVd), R 3 is hydrogen, halogen, or CI-3alkyl optionally substituted with I to 5 R2° groups. 101761 In certain embodiments of a compound of Formula (J), (I), (II), (ha), (fib), (III), (111a), or (Mb), R3 is hydrogen, Cl, or CH3. In certain embodiments of a compound 69 18435 of Formula (J), (I), (II), (lb), (11b), (III), (111a), (111b), (IV), (IVa), (IVb) or (IVd), R 3 is hydrogen, CI, or CH3. 101771 In certain embodiments of a compound of Formula (J), R I° is hydrogen, F, Cl, or CH3. 101781 In certain embodiments of a compound of Formula (3), R' ° is hydrogen. (01791 In certain embodiments of a compound of Formula (3), (I), (II), (Ha), (Ilb), (III), (IIIa), or (Mb), R I, R2, and R3 are hydrogen. In certain embodiments of a compound of Formula (3), (I), (II), (lb), (11b), (III), (111a), (111b), (IV), (IVa), (IVb), ((lVc), or (IVd), R I, R2, and R3 are hydrogen. 101801 In certain embodiments of a compound of Formula (J), (I), (II), (lb), (11b), (III), (111a), or (111b), R' and R3 are hydrogen and R2 is F. In certain embodiments of a compound of Formula (J), (I), (II), (Ha), (11b), (III), (111a), (111b), (IV), (IVa), (IVb), (IVc), or (IVd), IV and R3 are hydrogen and R2 is F. 101811 It is understood that each of the variables (e.g. R I, R2, R3, 114) may be combined with any other variables for Formula (3), (I), (II), (11a) or (lib) (e.g. RI, R2, R3, R4) Further, in instances describing a compound of Formula (J) or (I), it is understood that the variables also describe compounds of other formulae (e.g. Formula (II), (lb), (11b), (III), (111a), and (Mb)) which fall within the scope of Formula (I) or (I). 101821 It is understood that any variable for R' of Formula (J), (I), (II), (11a), (11b), (III), (111a), or (1Hb) may be combined with any variable of K 4 in Formula (J), (I), (II), (11a), (11b), (III), (Ilia), or (111b), the same as if each and every combination were specifically and individually listed. For example, in one variation of Formula (J) or (I), R' is hydrogen, Cl, CH3 or CF3, and R4 is C14 alkyl which is optionally substituted with 1 or 2 substituents independently selected from OH, CF3,-C(0)011, -C(0)0CH3, - C(0)NH2, SCH3,-C(0)NHCH3, -C(0)NHCH2C112NH2, -C(0)NHCII2CH2OH, - C(0)NHCH2-pyridyl, phenyl, tetrahydrofuranyl, and cyclopropyl 101831 It is understood that any variable for R 2 of Formula (J), (I), (II), (11a), (11b), (III), (111a), or (111b) may be combined with any variable of K4 in Formula (J), (1), (II), (Ha), (11b), (III), (Ilia), or (111b), the same as if each and every combination were specifically and individually listed. For example, in one variation of Formula (J) or (I), R2 is hydrogen, CH3, -CH2CH3 ,F, Br, CI, or CN, and 11 4 is C14 alkyl which is optionally 70 18435 substituted with I or 2 substituents independently selected from OH, CF3,—C(0)0H, — C(0)0CH3, —C(0)N112, SCH3,—C(0)NHCH3, —C(0)NFICH2CH2NH2, — C(0)NHCH2C1120H, —C(0)NHCH2-pyridyl, phenyl, tetrahydrofuranyl, and cyclopropyl. [01841 It is understood that any variable for R 3 of Formula (J), (1), (II), (1Ia), (llb), (III), (Ina), or (IIIb) may be combined with any variable of R 4 in Formula (J), (I), (II), (IIa), (11b), (III), (Ma), or (111b), the same as if each and every combination were specifically and individually listed. For example, in one variation of Formula (I) or (I), R3 is hydrogen, Cl, or CH3, and 12.4 is Cl.salkyl which is optionally substituted with I or 2 substituents independently selected from OH, CF3,—C(0)0H, —C(0)0CH3, —C(0)N1-12, SCH3, —C(0)NHCH3, —C(0)NHCH2C11211H2, —C(0)NHCH2C1120H, —C(0)NHCH2- pyridyl, phenyl, tetrahydrofuranyl, and cyclopropyl. 101851 In certain embodiments, the compound of Formula (J) or (I), or a pharmaceutically acceptable salt thereof, has one or more features selected from: (a) R4 is CIA alkyl which is optionally substituted with 1 or 2 substituents independently selected halogen, -OR', —C(0)011", —SR'„ Cmcycloalkyl, 3 to 6 membered heterocyclyl and C6-lo aryl; wherein each C3-6cycloalkyl and C6.10 aryl is optionally substituted with 1 to 3 R21 groups and wherein It' and R b are each independently hydrogen or Ci4alkyl, wherein each C1.4 alkyl is optionally substituted with —NH2. OH, or pyridyl; (b) IV is hydrogen, halogen, or Cialkyl optionally substituted with I to 5 R2° groups; (c) R2 is hydrogen, halogen, CN, or CI-alkyl optionally substituted with 1 to 5 R2° groups; and (d) R3 is hydrogen, halogen, or CI4alkyl optionally substituted with I to 5 R 2° groups. In certain embodiments, the compound of Formula (J) or (I), or a pharmaceutically acceptable salt thereof has two or more features selected from (a)-(d), as listed above. In certain embodiments, the compound of Formula (J) or (I), or a pharmaceutically acceptable salt thereof has three or more features selected from (a)-(d), as listed above. In certain embodiments, the compound of Formula (J) or (I), or a pharmaceutically acceptable salt thereof has four features selected from (a)-(d), as listed above. 71 18435 101861 In certain embodiments, the compound of Formula (J) or (I), or a pharmaceutically acceptable salt thereof has one or more features selected from (e) le is C1-6 alkyl which is optionally substituted with I or 2 substituents independently selected from OH, CF3,—C(0)0H, —C(0)00-13, — C(0)NH2, SCH3,—C(0)NHCH3, —C(0)NHCH2CH2NH2, — C(0)NHCH2CH2OH, —C(0)NHCH2-pyridyl, phenyl, tetrahydrofuranyl, and cyclopropyl. (0 RI is hydrogen, halogen, or C1.3alkyl optionally substituted with I to 5 halogens; (g) R2 is hydrogen, halogen, CN or C1.3alkyl optionally substituted with I to 5 halogens; and (h) R3 is hydrogen, halogen, or Claalkyl. In certain embodiments, the compound of Formula (J) or (I), or a pharmaceutically acceptable salt thereof has two or more features selected from (e)-(h), as listed above. In certain embodiments, the compound of Formula (J) or (I), or a pharmaceutically acceptable salt thereof has three or more features selected from (e)-(h), as listed above. In certain embodiments, the compound of Formula (J) or (I), or a pharmaceutically acceptable salt thereof has two or more features selected from (e)-(h), as listed above. 101871 In certain embodiments, the compound of Formula (I) or (I) is selected from: 72 18435 FINCH NH2 NH2 HNW NH2 NH2 NH2 LOH HN HN) OH N.- NH2 N.- NH2 NH2 OH HN NH2 NH2 CI OH N.- NH2 NH2 HNeCC;c1 N.-. NH2 N.-. NH2 73 18435 1.„,OH NH2 CI NH2 2,..„OH HN HN` ,211, NH2 CON OH HN r HN HN OR OH N N 2 and N NH2 ; or a pharmaceutically acceptable salt thereof. 101881 In certain embodiments, the compound of Formula (I) or (I) is selected from: 74 18435 OH TF. N.1_,..OH N I. N HfiN.... „OH ....--HN1...„.0H N CI lc NH2 c1....,,OHi OH N N ...III... II, .... NH2 N N.... NH2 CI eCOT:1 HN N .....Nt... N COH ...CON HN HN N N t%I... NH2 N.... NH2 F N 75 18435 OH HN and F N NH2 ; or a pharmaceutically acceptable salt thereof. 101891 In certain embodiments, the compound of Formula (J) or (I) is selected from: OH NW. HN2-" .11 NH2 CI NI-12 HN,OHC and NI-12 ; or a pharmaceutically acceptable salt thereof. 101901 In certain embodiments, the compound of Formula (J) is selected from: